腫瘍病理鑑別診断アトラス　肺癌　第2版

出版社： 文光堂
著者：
発行日： 2022-11-01
分野： 臨床医学：基礎  >  臨床病理学
ISBN： 9784830622618
シリーズ： 腫瘍病理鑑別診断アトラス
電子書籍版： 2022-11-01 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

18,700 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

18,700 円(税込)

購入する

商品紹介

腫瘍病理鑑別診断シリーズ「肺癌」，待望の第2版．2021年にはWHO分類第5版が発行されたほか，分子標的治療や免疫チェックポイント阻害薬の導入など，当該領域を取り巻く環境は日々変化している．そうした状況を踏まえて，肺腫瘍病理のエキスパートが精選した病理写真とともに，定義や概念，診断上の要点を解説．病理診断に必須の形態学的特徴を理解しつつ，鑑別ポイントをも網羅．さらに臨床との連携では欠かせないX線所見のみかたや治療法も解説した．

目次

  • 第1部　検鏡前の確認事項
    　I．肺癌総論
    　　1．肺の構造，組織
    　　2．肺癌の分子生物学
    　　3．肺癌のTNM分類と取扱い規約
    　II．病理標本の扱い方
    　　1．生検材料（経気管支，CTガイド下，cryobiosy）の取扱い
    　　2．細胞診検体の取扱い
    　　3．手術材料の取扱い（VATSを含む）

    第2部　組織型と診断の実際
    　I．上皮性腫瘍
    　A．良性腫瘍
    　　1．乳頭腫（扁平上皮，腺上皮，扁平上皮腺上皮混合型）
    　　2．腺腫（肺胞腺腫，乳頭腺腫，唾液腺型腺腫，粘液囊胞腺腫）
    　　3．硬化性肺胞上皮腫
    　　4．気管支腺腫・CMPT
    　B．悪性腫瘍
    　　1．前浸潤性病変
    　　（1）扁平上皮異形成，上皮内（扁平上皮）癌
    　　（2）異型腺腫様過形成，上皮内腺癌
    　（3）びまん性特発性肺神経内分泌細胞過形成
    　　2．扁平上皮癌
    　　（1）扁平上皮癌（角化型，非角化型，類基底細胞型）
    　　（2）リンパ上皮腫様癌
    　　3．腺癌
    　　（1）微少浸潤性腺癌
    　　（2）浸潤性腺癌
    　　（3）特殊性浸潤性腺癌
    　　　　a．浸潤性粘液性腺癌
    　　　　b．コロイド腺癌
    　　　　c．胎児型腺癌（低，高悪性度）
    　　　　d．腸型腺癌
    　　4．大細胞癌
    　　5．腺扁平上皮癌
    　　6．肉腫様癌
    　　（1）多型癌，癌肉腫
    　　（2）肺芽腫
    　　7．神経内分泌腫瘍
    　　（1）カルチノイド
    　　（2）大細胞神経内分泌癌
    　　（3）小細胞癌
    　　8．唾液腺型癌
    　　（1）唾液腺型腫瘍（粘表皮癌，腺様囊胞癌）
    　　（2）稀な唾液腺型癌
    　　9．その他の上皮性腫瘍
    　　（1）NUT癌
    　　（2）胸部SMARCA4欠損未分化腫瘍
    　II．非上皮性腫瘍
    　A．軟部組織腫瘍
    　　1．肺過誤腫，肺軟骨腫，びまん性肺リンパ管腫症
    　　2．胸膜肺芽腫，血管内膜肉腫，先天性気管支周囲筋線維芽細胞腫，原発性肺粘液性肉腫
    　　3．PEComatous腫瘍（LAM，PEComa）
    　　4．炎症性筋線維芽細胞腫瘍，デスモイド線維腫症，孤立性線維性腫瘍，石灰化線維性腫瘍
    　　5．類上皮血管内皮腫，血管腫，脂肪肉腫
    　　6．滑膜肉腫，小円形細胞肉腫
    　III．リンパ組織増殖性疾患
    　　1．MALTリンパ腫
    　　2．びまん性大細胞型B細胞リンパ腫，血管内大細胞型B細胞リンパ腫
    　　3．リンパ腫様肉芽腫症，節外性NK／T細胞リンパ腫，鼻型
    　　4．組織球性腫瘍（PLCH，ECD）
    　IV．転移性肺腫瘍
    　　1．悪性腫瘍の転移
    　　2．良性腫瘍の転移（平滑筋腫，多型腺腫，脊索腫）
    　V．腫瘍様病変
    　　1．多発性増殖性病変（テューモレット，微小肺髄膜細胞様結節，多巣性小結節性肺胞上皮過形成）
    　　2．炎症性疾患（IgG4関連肺疾患，限局性器質化肺炎，気管支炎症性ポリープ）
    　　3．感染症（抗酸菌症，真菌症，寄生虫症）
    　　4．その他（アミロイドーシス，子宮内膜症，肺分画症，肺動静脈瘻／
    　　　　　　　　　肺動静脈奇形，硝子化肉芽腫，サルコイドーシス
    　VI．家族性腫瘍（Carney triad，生殖細胞系列EGFR/HER2 変異）

    第3部　鑑別ポイント
    　I．腺癌浸潤径測定の実際
    　II．迅速診断の評価
    　III．低分化な癌の免疫染色評価
    　IV．胸膜中皮腫との鑑別
    　V．生検評価の注意点

    第4部　臨床との連携
    　I．術前診断：画像所見
    　II．術前・術中細胞診
    　III．治療
    　　1．肺癌治療総論（外科）
    　　2．肺癌治療総論（内科・化学療法）
    　　3．分子標的治療
    　　4．免疫チェックポイント阻害薬治療
    　IV．病理診断報告書の記載
    　　1．生検検体
    　　2．手術検体
    　　3．治療効果判定

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

P.9 掲載の参考文献
1) 日本肺癌学会 (編) : 臨床・病理 肺癌取扱い規約, 第8版補訂版, 金原出版, 2021
 
2) 松本武四郎 : 組織と器官. 岩波講座・現代生物科学 12, 岩波書店, 1977
 
3) Usmani OS, Dhand R, Lavorini F et al : Why We Should Target Small Airways Disease in Our Management of Chronic Obstructive Pulmonary Disease. May Clin Proc 96 : 2448-2463, 2021
PubMed
4) Branchfield K, Nantie L, Verheyden JM et al : Pulmonary neuroendocrine cells function as airway sensors to control lung immune response. Science 351 : 707-710, 2016
PubMed
5) Gehr P, Bachofen M, Weibel ER : The normal human lung : ultrastructure and morphometric estimation of diffusion capacity. Respir Physiol 32 : 121-140, 1978
PubMed
6) Crapo JD, Barry BE, Gehr P et al : Cell numbers and cell characteristics of the normal human lung. Am Rev Respir Dis 126 : 332-337, 1982
PubMed
7) Olmeda B, Martinez-Calle M, Perez-Gil J : Pulmonary surfactant metabolism in the alveolar airspace : biogenesis, extracellular conversions, recycling. Ann Anat 209 : 78-92, 2017
PubMed
8) Watson A, Madsen J, Clark HW : SP-A and SP-D : Dual Functioning Immune Molecules With Antiviral and Immunomodulatory Properties. Front Immunol 19 : 622598, 2021
 
9) Cordingley JL : Pores of Kohn. Thorax 27 : 433-441, 1972
PubMed
10) Berendt RF, Knutsen GL, Powanda MC : Nonhuman primate model for the study of respiratory Klebsiella pneumoniae infection. Infect Immun 22 : 275-281, 1978
 
11) Lambert MW : Accessory bronchiole-alveolar communications. J Pathol Bacteriol 70 : 311-314, 1955
 
12) Vidarsdottir H, Tran L, Nodin B et al : Comparison of Three Different TTF-1 Clones in Resected Primary Lung Cancer and Epithelial Pulmonary Metastases. Am J Clin Pathol 24 : 533-544, 2018
 
13) Hirano T, Auer G, Maeda M et al : Human Tissue Distribution of TA02, Which is Homologous with a New Type of Aspartic Proteinase, Napsin A. Jpn J Cancer Res 91 : 1015-1021, 2000
PubMed
14) Desai TJ, Brownfield DG, Krasnow A : Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature 507 : 190-194, 2014
 
15) Liu Q, Kuo Liu K, Guizhong Cui G et al : Lung regeneration by multipotent stem cells residing at the bronchioalveolarduct junction. Nat Genet 51 : 728-738, 2019
 
16) Burri PH : Cellular components of the alveolar unit. Curr Probl Clin Biochem 13 : 11-22, 1983
PubMed
17) Weibel ER, Crystal RC : Organization of the lung interstitium. in : Crystal RC, West JB, Weibel ER (eds) : "The Lung : Scientific Foundations", Lippincott-Raven Publishers, Philadelphia, 1997, pp685-695
 
18) Weibel ER : What makes a good lung? Swiss Med Wkly 139 : 375-386, 2009
PubMed
19) Ingber DE, Tensegrity I : Cell structure and hierarchical systems biology. J Cell Sci 116 : 1157-1173, 2003
PubMed
20) Reid L : The angiogram and pulmonary artery structure and branching (in the normal and with reference to disease). Proc R Soc Med 58 : 681-684, 1965
PubMed
21) Reid JA, Heard BE : The Capillary Network of Normal and Emphysematous Human Lungs Studies by Injections of Indian Ink. Thorax 18 : 201-212, 1963
 
22) Tomashefski JF Jr, Farver CF : Anatomy and histology of the lung. in : Cagle PH, Colors CF, Fraire AE (eds) : "Dail and Hammer's Pulmonar y Pathology Vol I", 3ed ed, Springer, New York, 2008, pp43-44
 
P.14 掲載の参考文献
1) Lynch TJ, Bell DW, Sordella R et al : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 : 2129-2139, 2004
PubMed
2) Paez JG, Janne PA, Lee JC et al : EGFR mutations in lung cancer : correlation with clinical response to gefitinib therapy. Science 304 : 1497-1500, 2004
PubMed
3) Weinstein IB, Joe A : Oncogene addiction. Cancer Res 68 : 3077-3080 ; discussion 3080, 2008
PubMed
4) Weinstein IB : Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science 297 : 63-64, 2002
PubMed
5) Mok TS, Wu YL, Thongprasert S et al : Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 : 947-957, 2009
 
6) Goto K, Satouchi M, Ishii G et al : An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol 23 : 2914-2919, 2012
PubMed
7) Tan AC, Tan DSW : Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. J Clin Oncol JCO2101626, 2022
PubMed
8) George J, Lim JS, Jang SJ et al : Comprehensive genomic profiles of small cell lung cancer. Nature 524 : 47-53, 2015
PubMed
9) Rudin CM, Poirier JT, Byers LA et al : Molecular subtypes of small cell lung cancer : a synthesis of human and mouse model data. Nat Rev Cancer 19 : 289-297, 2019
 
10) Cancer Genome Atlas Research Network : Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 : 543-550, 2014
 
11) Cancer Genome Atlas Research Network : Comprehensive genomic characterization of squamous cell lung cancers. Nature 489 : 519-525, 2012
 
12) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Thoracic Tumours, 5th ed, IARC, Lyon, 2021
 
P.19 掲載の参考文献
1) Brierly JD, Gospodarowicz MK, Wittekind C : TNM Classification of Malignant Tumours, 8th ed, Wiley Blackwell, Oxford, 2017
 
2) Amin MB, Edge SB, Greene FL et al (eds) : AJCC Cancer Staging Manual, 8th ed, Springer International Publishing, New York, 2017
 
3) Rami-Porta R (ed) : Staging Handbook in Thoracic Oncology, 2nd ed, Editorial Rx Press, North Fort Myers, 2016
 
4) 日本肺癌学会 (編) : 臨床・病理 肺癌取扱い規約, 第8版補訂版, 金原出版, 2021
 
5) Travis WD, Dacic S, Wistuba I et al : IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. J Thorac Oncol 15 : 709-740, 2020
PubMed
6) Stein JE, Lipson EJ, Cottrell TR et al : Pan-Tumor Pathologic Scoring of Response to PD- (L) 1 Blockade. Clin Cancer Res 26 : 545-551, 2020
 
7) Detterbeck FC, Franklin WA, Nicholson AG et al : The IASLC Lung Cancer Staging Project : Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 11 : 651-665, 2016
PubMed
8) Detterbeck FC, Nicholson AG, Franklin WA et al : The IASLC Lung Cancer Staging Project : Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol 11 : 639-650, 2016
PubMed
9) Sonobe M, Date H, Wada H et al : Prognostic factors after complete resection of pN2 non-small cell lung cancer. J Thorac Cardiovasc Surg 146 : 788-795, 2013
PubMed
P.24 掲載の参考文献
1) Travis WD, Brambilla E, Noguchi M et al : International Association for the Study of Lung Cancer-American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6 : 244-285, 2011
 
2) Travis WD, Brambilla E, Berke AP et al (eds) : WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th ed, IARC Press, Lyon, 2015
 
3) Arimura K, Tagaya E, Akagawa H et al : Cryobiopsy with endobronchial ultrasonography using a guide sheath for peripheral pulmonary lesions and DNA analysis by next generation sequencing and rapid on-site evaluation. Respir Investig 57 : 150-156, 2019
PubMed
4) 日本病理学会 (編) : ゲノム研究用・診療用病理組織検体取扱い規程, 羊土社, 2019
 
5) 日本肺癌学会 (編) : 肺癌診療ガイドライン 2020年版, 第6版, 金原出版, 2021
 
6) 日本肺癌学会バイオマーカー委員会 (編) : 肺癌患者における次世代シークエンサーを用いた遺伝子パネル検査の手引き, 第2.0版, 2021
 
7) 岩田英紘, 恒川佳未結, 新田憲司 他 : 良好な核酸品質保持のためのホルマリン固定条件の検討-Friday biopsyや長期休暇前に採取された生検検体を想定して-. 医学検査 70 : 724-732, 2021
Medical*Online
P.29 掲載の参考文献
1) 公益社団法人 日本臨床細胞学会ゲノム診療時代における細胞診のあり方検討ワーキンググループ : がんゲノム診療における細胞検体の取扱い指針, 第1.0版. 2021
 
2) 日本肺癌学会バイオマーカー委員会 : 肺癌患者における次世代シークエンサーを用いた遺伝子パネル検査の手引き, 第1.1版. 2021
 
3) Kanagal-Shamanna R, Portier BP, Singh RR et al : Nextgeneration sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples : promises and challenges for routine clinical diagnostics. Mod Pathol 27 : 314-327, 2014
PubMed
4) Balla A, Hampel KJ, Sharma MK et al : Comprehensive validation of cytology specimens for next-generation sequencing and clinical practice experience. J Mol Diagn 20 : 812-821, 2018
PubMed
5) Roy-Chowdhuri S, Goswami RS, Chen H et al : Factors affecting the success of next-generation sequencing in cytology specimens. Cancer Cytopathol 123 : 659-668, 2015
PubMed
6) Roy-Chowdhuri S, Stewart J : Preanalytic variables in cytology : lessons learned from next-generation sequencing-the MD Anderson experience. Arch Pathol Lab Med 140 : 1191-1199, 2016
 
7) Bellevicine C, Malapelle U, Vigliar E et al : How to prepare cytological samples for molecular testing. J Clin Pathol 70 : 819-826, 2017
PubMed
8) 池田徳彦, 川本雅司, 佐藤之俊 : 呼吸器・胸腺検体別処理法. 公益社団法人 日本臨床細胞学会 (編) : 細胞診ガイドライン 4 呼吸器・胸腺・体腔液・リンパ節. 金原出版, 2015, pp29-32
 
9) Matsuo Y, Yoshida T, Yamashita K et al : Reducing DNA damage by formaldehyde in liquid-based cytology preservation solutions to enable the molecular testing of lung cancer specimens. Cancer Cytopathol 126 : 1011-1021, 2018
PubMed
10) Araki Y, Arihiro K, Yamaguchi K et al : Analysis of micro RNA expression in liquid-based cytology samples may be useful for primary lung cancer diagnosis. Am J Clin Pathol 156 : 644-652, 2021
PubMed
11) Uchihata Y, Arihiro K, Kaneko K et al : Analysis of micro RNA in bile cytologic samples is useful for detection and diagnosis of extrahepatic cholangiocarcinoma. Am J Clin Pathol 158 : 122-131, 2022
 
P.36 掲載の参考文献
1) 日本肺癌学会 (編) : 肺癌診療ガイドライン 2020年度版, 金原出版, 2021, pp55-60
 
2) 日本病理学会 (編) : ホルマリン固定パラフィン包埋組織・細胞検体の適切な取扱い. ゲノム研究用・診療用病理組織検体取り扱い規定, 羊土社, 2019, pp129-154
 
3) 日本肺癌学会 (編) : 肺癌取扱い規約, 第8版補訂版, 金原出版, 2021, pp77-81
 
4) 中井登紀子, 大林千穂 : 外科的切除検体の取り扱い. 最新肺癌学 基礎と臨床の最新研究動向, 日本臨牀 71 (増刊6) : 399-403, 2013
 
5) 岡輝明 : 肺構造の特徴を踏まえた呼吸器疾患の形態学的観察法. 病理と臨床 32 : 955-969, 2014
Medical*Online
P.41 掲載の参考文献
1) Flieder DB, Agaimy A : Bronchial papilloma. in : WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed [Internet], IARC, Lyon, 2021 [cited 2022 Feb 01]. Available from : https://tumourclassification.iarc.who.int/chapters/35
 
2) 中谷行雄, 元井紀子 : 肺・胸膜の腫瘍. 外科病理学, 第5版, 文光堂, 2020, pp305-378
 
3) Popper HH, el-Shabrawi Y, Wockel W et al : Prognostic importance of human papilloma virus typing in squamous cell papilloma of the bronchus : comparison of in situ hybridization and the polymerase chain reaction. Hum Pathol 25 : 1191-1197, 1994
PubMed
4) Popper HH, Wirnsberger G, Juttner-Smolle FM et al : The predictive value of human papilloma virus (HPV) typing in the prognosis of bronchial squamous cell papillomas. Histopathology 21 : 323-330, 1992
PubMed
5) Lagana SM, Hanna RF, Borczuk AC : Pleomorphic (spindle and squamous cell) carcinoma arising in a peripheral mixed squamous and glandular papilloma in a 70-year-old man. Arch Pathol Lab Med 135 : 1353-1356, 2011
 
6) Harada H, Miura K, Tsutsui Y et al : Solitary squamous cell papilloma of the lung in a 40-year-old woman with recurrent lar yngeal papillomatosis. Pathol Int 50 : 431-439, 2000
 
7) Flieder DB, Koss MN, Nicholson A et al : Solitary pulmonary papillomas in adults : a clinicopathologic and in situ hybridization study of 14 cases combined with 27 cases in the literature. Am J Surg Pathol 22 : 1328-1342, 1998
PubMed
8) Larson DA, Derkay CS : Epidemiology of recurrent respiratory papillomatosis. APMIS 118 : 450-454, 2010
PubMed
9) Tryfon S, Dramba V, Zoglopitis F et al : Solitary papillomas of the lower airways : epidemiological, clinical, and therapeutic data during a 22-year period and review of the literature. J Thorac Oncol 7 : 643-648, 2012
PubMed
P.47 掲載の参考文献
1) Burke LM, Rush WI, Khoor A et al : alveolar adenoma : a histochemical, immunohistochemical, and ultrastructural analysis of 17 cases. Hum Pathol 30 : 158-167, 1999
PubMed
2) Okada S, Ohbayashi C, Nishimura M et al : Malignant transformation of alveolar adenoma to papillary adenocarcinoma : a case report. J Thorac Dis 8 : E358-E361, 2016
PubMed
3) Cavazza A, Paci M, De marco L et al : Alveolar adenoma of the lung : a clinicopathologic, immunohistochemical, and molecular study of an unusual case. Int J Surg Pathol 12 : 155-159, 2004
 
4) Beasley MB, Sauter JL : Papillary adenoma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp46-47
 
5) Masunaga A, Nagashio R, Iwamoto S et al : A case of pulmonary papillary adenoma : Possible relationship between tumor histogenesis/tumorigenesis and fibroblast growth factor receptor 2 IIIb. Pathol Int 62 : 640-645, 2012
PubMed
6) Yoshida A, Beasley MB : Mucous gland adenoma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp53-54
 
7) Mehrad M, Farver CF, Nicholson AG : Pleomorphic adenoma of the lung. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp115-116
 
8) Nakaguro M, Mino-Kenudson M, Urano M et al : Sialadenoma papilliferum of the bronchus : An unrecognized bronchial counterpart of the salivary gland tumor with frequent BRAF V600E mutations. Am J Surg Pathol 45 : 662-671, 2021
PubMed
9) Sasaki E, Iwakoshi A, Masago K et al : Sialadenoma papilliferum of the bronchus : focus on histological and genetic distinction from mixed squamous cell and glandular papilloma. Pathology 53 : 788-790, 2021
PubMed
10) Yoshida A, Beasley MB : Mucinous cystadenoma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp51-52
 
P.51 掲載の参考文献
1) Chan AC, Chan JK : Can pulmonary sclerosing haemangioma be accurately diagnosed by intra-operative frozen section? Histopathology 41 : 392-403, 2002
PubMed
2) Wang EH, Dai SD, Qi FJ et al : Gene expression and clonality analysis of the androgen receptor and phosphoglycerate kinase genes in polygonal cells and cuboidal cells in socalled pulmonary sclerosing hemangioma. Mod Pathol 20 : 1208-1215, 2007
PubMed
3) Jung SH, Kim MS, Lee SH et al : Whole-exome sequencing identifies recurrent AKT1 mutations in sclerosing hemangioma of lung. Proc Natl Acad Sci U S A 113 : 10672-10677, 2016
PubMed
4) Liu W, Tian XY, Li Y et al : Coexistence of pulmonary sclerosing hemangioma and primary adenocarcinoma in the same nodule of lung. Diagn Pathol 6 : 41, 2011
 
5) Wang Z, Yang MQ, Huang WJ et al : Sclerosing pneumocytoma mixed with a typical carcinoid tumor : A case report and review of literature. Medicine (Baltimore) 98 : e14315, 2019
 
P.55 掲載の参考文献
1) 石川雄一 : 肺末梢の線毛性粘液結節性乳頭状腫瘍 : 良性か悪性か? 病理と臨床 20 : 964-965, 2002
Medical*Online
2) Chang JC, Montecalvo J, Borsu L et al : : Bronchiolar Adenoma : Expansion of the Concept of Ciliated Muconodular Papillary Tumors With Proposal for Revised Terminology Based on Morphologic, Immunophenotypic, and Genomic Analysis of 25 Cases. Am J Surg Pathol 42 : 1010-1026, 2018
PubMed
3) Kamata T, Sunami K, Yoshida A et al : Frequent BRAF or EGFR Mutations in Ciliated Muconodular Papillary Tumors of the Lung. J Thorac Oncol 11 : 261-265, 2016
PubMed
4) Taguchi R, Higuchi K, Sudo M et al : A case of anaplastic lymphoma kinase (ALK) -positive ciliated muconodular papillary tumor (CMPT) of the lung. Pathol Int 67 : 99-104, 2017
PubMed
5) Udo E, Furusato B, Sakai K et al : Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation. Diagn Pathol 12 : 62, 2017
PubMed
P.58 掲載の参考文献
1) 日本肺癌学会 (編) : 肺癌取扱い規約, 第8版補訂版, 金原出版, 2021, p97
 
2) Herth FJ, Eberhardt R, Anantham D et al : Narrow-band imaging bronchoscopy increases the specificity of bronchoscopic early lung cancer detection. J Thorac Oncol 4 : 1060-1065, 2009
PubMed
3) Wistuba I, Lam S, Behrens C et al : Molecular Damage in the Bronchial Epithelium of Current and Former Smokers. J Natl Cancer Inst 89 : 1366-1373, 1997
PubMed
P.64 掲載の参考文献
1) Travis WD, Colby TV, Corrin B et al (eds) : Histological Typing of Lung and Pleural Tumours, Springer, Berlin, 1999
 
2) Travis WD, Brambilla E, Noguchi M et al : International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thoracic Oncol 6 : 244-285, 2011
 
3) Yokose T, Doi M, Tanno K et al : Atypical adenomatous hyperplasia of the lung in autopsy cases. Lung Cancer 33 : 155-161, 2001
PubMed
4) Yokose T, Ito Y, Ochiai A : High prevalence of atypical adenomatous hyperplasia of the lung in autopsy specimens from elderly patients with malignant neoplasms. Lung Cancer 29 : 125-130, 2000
PubMed
5) Kerr KM : Pulmonary preinvasive neoplasia. J Clin Pathol 54 : 257-271, 2001
PubMed
6) Ullmann R, Bongiovanni M, Halbwedl I et al : Is high-grade adenomatous hyperplasia an early bronchioloalveolar adenocarcinoma? J Pathol 201 : 371-376, 2003
PubMed
7) Minami Y, Matsuno Y, Iijima T et al : Prognostication of small-sized primary pulmonary adenocarcinomas by histopathological and karyometric analysis. Lung Cancer 48 : 339-348, 2005
PubMed
8) Sakamoto H, Shimizu J, Horio Y et al : Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol 212 : 287-294, 2007
PubMed
9) Sivakumar S, Lucas FAS, McDowell TL et al : Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Res 77 : 6119-6130, 2017
PubMed
10) Hashizume T, Yamada K, Okamoto N et al : Prognostic significance of thin-section CT scan findings in small-sized lung adenocarcinoma. Chest 133 : 441-447, 2008
PubMed
11) Travis WD, Asamura H, Bankier AA et al : The IASLC Lung Cancer Staging Project : Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol 11 : 1204-1223, 2016
PubMed
12) Jones KD : Whence Lepidic? The history of a Canadian neologism. Arch Pathol Lab Med 137 : 1822-1824, 2013
PubMed
13) Noguchi M, Morikawa A, Kawasaki M et al : Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 75 : 2844-2852, 1995
PubMed
14) Yim J, Zhu LC, Chiriboga L et al : Histologic features are important prognostic indicators in early stage lung adenocarcinomas. Modern Pathol 20 : 233-241, 2007
 
P.66 掲載の参考文献
1) Agaguyo SM, Miller YE, Waldron JA Jr, et al : Brief report : idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. N Engl J Med 327 : 1285-1288, 1992
 
2) Davies SJ, Gosney JR, Hansell DM, et al : Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia : an underrecognized spectrum of disease. Thorax 62 : 248-252, 2007
 
3) Rossi G, Cavazza A, Spagnolo P, et al : Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome. Eur Respir J 47 : 1829-1841, 2016
PubMed
4) Mengoli MC, Rossi G, Cavazza A, et al : Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) syndrome and carcinoid tumors with/without NECH : a clinicopathologic, radiologic, and immunomolecular comparison study. Am J Sugr Pathol 42 : 646-655, 2018
 
5) Konnno S, Shigemura M, Ogi T, et al : Clinical course of histologically proven multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex : a case series and comparison with lymphagiomyomatosis. Respiration 95 : 310-316, 2018
 
6) Nassar AA, Jaroszewski DE, Helmers RA, et al : Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia : a systematic overview. Am J Respir Crit Care Med 184 : 8-16, 2011
PubMed
P.78 掲載の参考文献
1) Funai K, Yokose T, Ishii G et al : Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol 27 : 978-984, 2003
PubMed
2) 埴淵昌毅, 古川千幸, 篠原勉 : 17歳で発症した低分化型肺扁平上皮癌の1例. 肺癌 47 : 337-341, 2007
Medical*Online
3) 日本肺癌学会 (編) : 肺癌 診療ガイドライン 悪性胸膜中皮腫・胸腺腫瘍含む, 2020年版, 金原出版, 2021, pp56-58
 
4) Kadota K, Kushida Y, Katsuki N et al : Tumor Spread Through Air Spaces Is an Independent Predictor of Recurrence-free Survival in Patients With Resected Lung Squamous Cell Carcinoma. Am J Surg Pathol 41 : 1077-1086, 2017
PubMed
5) Watanabe Y, Yokose T, Sakuma Y et al : Alveolar space filling ratio as a favorable prognostic factor in small peripheral squamous cell carcinoma of the lung. Lung Cancer 73 : 217-221, 2011
PubMed
6) Neppl C, Zlobec I, Schmid RA et al : Validation of the International Tumor Budding Consensus Conference (ITBCC) 2016 recommendation in squamous cell carcinoma of the lung-a single-center analysis of 354 cases. Mod Pathol 33 : 802-811, 2020
 
7) Hayashi T, Takamochi K, Yanai Y et al : Non-small cell lung carcinoma with diffuse coexpression of thyroid transcription factor-1 and deltaNp63/p40. Hum Pathol 78 : 177-181, 2018
PubMed
8) Wistuba I, Lam S, Behrens C et al : Molecular Damage in the Bronchial Epithelium of Current and Former Smokers. J Natl Cancer Inst 89 : 1366-1373, 1997
PubMed
9) Cancer Genome Atlas Research Network : Comprehensive genomic characterization of squamous cell lung cancers. Nature 489 : 519-525, 2012
 
10) Yuan G, Flores NM, Hausmann S et al : Elevated NSD3 histone methylation activity drives squamous cell lung cancer. Nature 590 : 504-508, 2021
PubMed
11) Brambilla C, Laffaire J, Lantuejoul S et al : Lung squamous cell carcinomas with basaloid histology represent a specific molecular entity. Clin Cancer Res 20 : 5777-5786, 2014
PubMed
12) Miyagi J, Tsuhako K, Kinjo T et al : Recent striking changes in histological differentiation and rate of human papillomavirus infection in squamous cell carcinoma of the lung in Okinawa, a subtropical island in southern Japan. J Clin Pathol 53 : 676-684, 2000
PubMed
13) Goto A, Li CP, Ota S et al : Human papillomavirus infection in lung and esophageal cancers : analysis of 485 Asian cases. J Med Virol 83 : 1383-1390, 2011
 
14) Uematsu K, Yoshimura A, Gemma A et al : Aberrations in the fragile histidine triad (FHIT) gene in idiopathic pulmonary fibrosis. Cancer Res 61 : 8527-8533, 2001
PubMed
15) Hata A, Nakajima T, Matsusaka K et al : Genetic alterations in squamous cell lung cancer associated with idiopathic pulmonary fibrosis. Int J Cancer 148 : 3008-3018, 2021
PubMed
P.82 掲載の参考文献
1) 日本肺癌学会 (編) : 臨床・病理 肺癌取扱い規約, 第8版補訂版, 金原出版, 2021, p103, p107
 
2) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Thoracic Tumours, 5th ed, IARC, Lyon, 2021
 
3) Sasaki A, Kato T, Ujiie H et al : Primary pulmonary lymphoepithelioma-like carcinoma with positive expression of Epstein-Barr virus and PD-L1 : A case report. Int J Surg Case Rep 79 : 431-435, 2021
PubMed
4) Yeh YC, Kao HL, Lee KL et al : Epstein-Barr Virus-Associated Pulmonary Carcinoma : Proposing an Alternative Term and Expanding the Histologic Spectrum of Lymphoepithelioma-like Carcinoma of the Lung. Am J Surg Pathol 43 : 211-219, 2019
PubMed
5) Xie M, Wu X, Wang F et al : Clinical Significance of Plasma Epstein-Barr Virus DNA in Pulmonary Lymphoepithelioma-like Carcinoma (LELC) Patients. J Thorac Oncol 13 : 218-227, 2018
PubMed
6) Chang YL, Wu CT, Shih JY et al : New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas. Am J Surg Pathol 26 : 715-723, 2002
PubMed
7) Huber M, Pavlova B, Muhlberger H et al : Detection of the Epstein-Barr virus in primary adenocarcinoma of the lung with Signet-ring cells. Virchows Arch 441 : 25-30, 2002
PubMed
8) Hong S, Liu D, Luo S et al : The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma. Nat Commun 10 : 3108, 2019
PubMed
9) Chau SL, Tong JH, Chow C et al : Distinct Molecular Landscape of Epstein-Barr Virus Associated Pulmonary Lymphoepithelioma-Like Carcinoma Revealed by Genomic Sequencing. Cancers (Basel) 12 : 2065, 2020
PubMed
10) Yeh YC, Ho HL, Lin CI et al : Whole-exome Sequencing of Epstein-Barr Virus-associated Pulmonary Carcinoma With Low Lymphocytic Infiltration Shows Molecular Features Similar to Those of Classic Pulmonary Lymphoepithelioma-like Carcinoma : Evidence to Support Grouping Together as One Disease Entity. Am J Surg Pathol 45 : 1476-1486, 2021
PubMed
P.86 掲載の参考文献
1) Travis WD, Brambilla E, Noguchi M et al : International Association for the Study of Lung Cancer?American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thoracic Oncol 6 : 244-285, 2011
 
2) Minami Y, Matsuno Y, Iijima T et al : Prognostication of small-sized primary pulmonary adenocarcinomas by histopathological and karyometric analysis. Lung Cancer 48 : 339-348, 2005
PubMed
3) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Thoracic Tumours, 5th ed, IARC, Lyon, 2021
 
4) Sivakumar S, Lucas FAS, McDowell TL et al : Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Res 77 : 6119-6130, 2017
PubMed
P.98 掲載の参考文献
1) 日本肺癌学会 (編) : 肺癌取扱い規約, 第8版補訂版, 金原出版, 2021
 
2) Travis WD, Brambilla E, Burke AP et al (eds) : WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th ed, IARC Press, Lyon, 2015
 
3) Travis WD, Colby TV, Corrin B et al : WHO Histological Classification of Tumours, Histological Typing of Lung and Pleural Tumours, 3rd ed, Springer-Verlag, Berlin, 1999
 
4) Travis WD, Brambilla E, Muller-Hermelink HK et al (eds) : WHO Classification of Tumours, Pathology & Genetics, Tumours of the Lung, Pleura, Thymus and Heart, IARC Press, Lyon, 2004
 
5) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Thoracic Tumours, 5th ed, IARC Press, Lyon, 2021
 
6) Eguchi T, Yoshizawa A, Kawakami S et al : Tumor size and computed tomography attenuation of pulmonary pure ground-glass nodules are useful for predicting pathological invasiveness. PLoS One 9 : e97867, 2014
PubMed
7) Nakamura S, Fukui T, Taniguchi T et al : Prognostic impact of tumor size eliminating the ground glass opacity component : modified clinical T descriptors of the tumor, node, metastasis classification of lung cancer. J Thorac Oncol 8 : 1551-1557, 2013
PubMed
8) Machado Medeiros T, Altmayer S, Watte G et al : 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer : a systematic review and meta-analysis. Eur Radiol 30 : 3641-3649, 2020
 
9) Travis WD, Brambilla E, Noguchi M et al : International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6 : 244-285, 2011
 
10) Yanagawa N, Shiono S, Abiko M et al : The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma. J Thorac Oncol 11 : 1976-1983, 2016
PubMed
11) Nitadori J, Bograd AJ, Kadota K et al : Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller. J Natl Cancer Inst 105 : 1212-1220, 2013
PubMed
12) Moreira AL, Ocampo PSS, Xia Y et al : A Grading System for Invasive Pulmonary Adenocarcinoma : A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol 15 : 1599-1610, 2020
 
13) Rokutan-Kurata M, Yoshizawa A, Ueno K et al : Validation Study of the International Association for the Study of Lung Cancer Histologic Grading System of Invasive Lung Adenocarcinoma. J Thorac Oncol 16 : 1753-1758, 2021
 
14) Kadota K, Villena-Vargas J, Yoshizawa A et al : Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease. Am J Surg Pathol 38 : 448-460, 2014
 
15) Noguchi M, Morikawa A, Kawasaki M et al : Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer 75 : 2844-2852, 1995
PubMed
16) Thunnissen E, Belien JA, Kerr KM et al : In compressed lung tissue microscopic sections of adenocarcinoma in situ may mimic papillary adenocarcinoma. Arch Pathol Lab Med 137 : 1792-1797, 2013
PubMed
17) Kadota K, Nitadori JI, Sima CS et al : Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas. J Thorac Oncol 10 : 806-814, 2015
 
18) Moreira AL, Joubert P, Downey RJ et al : Cribriform and fused glands are patterns of high-grade pulmonary adenocarcinoma. Hum Pathol 45 : 213-220, 2014
PubMed
19) Kadota K, Yeh YC, Sima CS et al : The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma : a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. Mod Pathol 27 : 690-700, 2014
 
20) Warth A, Muley T, Kossakowski C et al : Prognostic impact and clinicopathological correlations of the cribriform pattern in pulmonary adenocarcinoma. J Thorac Oncol 10 : 638-644, 2015
PubMed
21) Kadota K, Kushida Y, Kagawa S et al : Cribriform Subtype is an Independent Predictor of Recurrence and Survival After Adjustment for the Eighth Edition of TNM Staging System in Patients With Resected Lung Adenocarcinoma. J Thorac Oncol 14 : 245-254, 2019
PubMed
22) Nakajima N, Yoshizawa A, Rokutan-Kurata M et al : Prognostic significance of cribriform adenocarcinoma of the lung : validation analysis of 1,057 Japanese patients with resected lung adenocarcinoma and a review of the literature. Transl Lung Cancer Res 10 : 117-127, 2021
 
23) Ohe M, Yokose T, Sakuma Y et al : Stromal micropapillary component as a novel unfavorable prognostic factor of lung adenocarcinoma. Diagn Pathol 7 : 3, 2012
PubMed
24) Emoto K, Eguchi T, Tan KS et al : Expansion of the Concept of Micropapillary Adenocarcinoma to Include a Newly Recognized Filigree Pattern as Well as the Classical Pattern Based on 1468 Stage I Lung Adenocarcinomas. J Thorac Oncol 14 : 1948-1961, 2019
 
25) Kondo K, Yoshizawa A, Nakajima N et al : Large nest micropapillary pattern of lung adenocarcinoma has poorer prognosis than typical floret pattern : analysis of 1,062 resected tumors. Transl Lung Cancer Res 9 : 587-602, 2020
PubMed
26) Yatabe Y, Dacic S, Borczuk AC et al : Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol 14 : 377-407, 2019
PubMed
27) Rokutan-Kurata M, Yoshizawa A, Nakajima N et al : Discohesive growth pattern (Disco-p) as an unfavorable prognostic factor in lung adenocarcinoma : an analysis of 1062 Japanese patients with resected lung adenocarcinoma. Mod Pathol 33 : 1722-1731, 2020
 
28) Yoshizawa A, Motoi N, Riely GJ et al : Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma : prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 24 : 653-664, 2011
 
29) Russell PA, Wainer Z, Wright GM et al : Does lung adenocarcinoma subtype predict patient survival? : A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 6 : 1496-1504, 2011
 
30) Sica G, Yoshizawa A, Sima CS et al : A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 34 : 1155-1162, 2010
 
31) Kadota K, Suzuki K, Kachala SS et al : A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol 25 : 1117-1127, 2012
 
32) Zhang M, Yoshizawa A, Kawakami S et al : The histological characteristics and clinical outcomes of lung cancer in patients with combined pulmonary fibrosis and emphysema. Cancer Med 5 : 2721-2730, 2016
PubMed
33) Onozato ML, Kovach AE, Yeap BY et al : Tumor islands in resected early-stage lung adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and worse prognosis. Am J Surg Pathol 37 : 287-294, 2013
PubMed
34) Blaauwgeers H, Flieder D, Warth A et al : A Prospective Study of Loose Tissue Fragments in Non-Small Cell Lung Cancer Resection Specimens : An Alternative View to "Spread Through Air Spaces". Am J Surg Pathol 41 : 1226-1230, 2017
PubMed
35) Shih AR, Mino-Kenudson M : Updates on spread through air spaces (STAS) in lung cancer. Histopathology 77 : 173-180, 2020
PubMed
36) Pelosi G, Fabbri A, Tamborini E et al : Challenging Lung Carcinoma with Coexistent DeltaNp63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. J Thorac Oncol 10 : 1500-1502, 2015
 
37) Ordonez NG : Napsin A expression in lung and kidney neoplasia : a review and update. Adv Anat Pathol 19 : 66-73, 2012
 
38) Sugano M, Nagasaka T, Sasaki E et al : HNF4α as a marker for invasive mucinous adenocarcinoma of the lung. Am J Surg Pathol 37 : 211-218, 2013
 
39) Motoi N, Szoke J, Riely GJ et al : Lung adenocarcinoma : modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol 32 : 810-827, 2008
PubMed
40) Yatabe Y, Kosaka T, Takahashi T et al : EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 29 : 633-639, 2005
PubMed
41) Yoshizawa A, Sumiyoshi S, Sonobe M et al : Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations : analysis of 440 Japanese patients. J Thorac Oncol 8 : 52-61, 2013
PubMed
42) Yoshida A, Tsuta K, Watanabe S et al : Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 72 : 309-315, 2011
PubMed
43) Zhou J, Zhao J, Zheng J et al : A Prediction Model for ROS1-Rearranged Lung Adenocarcinomas based on Histologic Features. PLoS One 11 : e0161861, 2016
 
44) Boland JM, Wampfler JA, Jang JS et al : Pulmonary adenocarcinoma with signet ring cell features : a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol 38 : 1681-1688, 2014
PubMed
45) Girard N, Deshpande C, Lau C et al : Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases. Am J Surg Pathol 33 : 1752-1764, 2009
PubMed
46) Nicholson AG, Torkko K, Viola P et al : Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung. J Thorac Oncol 13 : 205-217, 2018
 
47) Mansuet-Lupo A, Barritault M, Alifano M et al : Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. J Thorac Oncol 14 : 844-856, 2019
PubMed
48) Park E, Ahn S, Kim H et al : Targeted Sequencing Analysis of Pulmonary Adenocarcinoma with Multiple Synchronous Ground-Glass/Lepidic Nodules. J Thorac Oncol 13 : 1776-1783, 2018
PubMed
49) Detterbeck FC, Nicholson AG, Franklin WA et al : The IASLC Lung Cancer Staging Project : Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol 11 : 639-650, 2016
PubMed
P.102 掲載の参考文献
1) Nakaoku T, Tsuta K, Ichikawa H et al : Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res 20 : 3087-3093, 2014
PubMed
2) Shim HS, Kenudson M, Zheng Z et al : Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung. J Thorac Oncol 10 : 1156-1162, 2015
 
3) Kishikawa S, Hayashi T, Saito T et al : Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma. Mod Pathol 34 : 786-797, 2021
PubMed
4) Yang SR, Chang JC, Leduc C et al : Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions : Analysis of Clonal Relationship by Comparative Molecular Profiling. J Thorac Oncol 16 : 1188-1199, 2021
PubMed
5) Ichinokawa H, Ishii G, Nagai K et al : Clinicopathological characteristics of primary lung adenocarcinoma predominantly composed of goblet cells in surgically resected cases. Pathol Int 61 : 423-429, 2011
PubMed
6) Tsuta K, Ishii G, Nitadori J et al : Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin. J Pathol 209 : 78-87, 2006
PubMed
7) Yatabe Y, Koga T, Mitsudomi T et al : CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. J Pathol 203 : 645-652, 2004
 
8) Sugano M, Nagasaka T, Sasaki E et al : HNF4alpha as a marker for invasive mucinous adenocarcinoma of the lung. Am J Surg Pathol 37 : 211-218, 2013
PubMed
9) Nakajima N, Yoshizawa A, Nakajima T et al : GATA6-positive lung adenocarcinomas are associated with invasive mucinous adenocarcinoma morphology, hepatocyte nuclear factor 4alpha expression, and KRAS mutations. Histopathology 73 : 38-48, 2018
PubMed
P.106 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Thoracic Tumors, 5th ed. IARC, Lyon, 2021, pp81-82
 
2) Zenali MJ, Weissferdt A, Solis LM et al : An update on clinicopathological, immunohistochemical, and molecular profiles of colloid carcinoma of the lung. Hum Pathol 46 : 836-842, 2015
PubMed
3) Jurmeister P, Scholer A, Arnold A et al : DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer. Mod Pathol 32 : 855-865, 2019
PubMed
4) Sonzogni A, Bianchi F, Fabbri A et al : Pulmonary adenocarcinoma with mucin production modulates phenotype according to common genetic traits : a reappraisal of mucinous adenocarcinoma and colloid adenocarcinoma. J Pathol Clin Res Mar 3 : 139-152, 2017
PubMed
5) Guo M, Tomoshige K, Meister M et al : Gene signature driving invasive mucinous adenocarcinoma of the lung. EMBO Mol Med 9 : 462-481, 2017
PubMed
P.110 掲載の参考文献
1) Nakatani Y, Kitamura H. Inayama Y et al : Pulmonary adenocarcinomas of the fetal lung type : a clinicopathologic study indicating differences in histology, epidemiology, and natural history of low-grade and high-grade forms. Am J Surg Pathol 22 : 399-411, 1998
PubMed
2) 中谷行雄, 元井紀子 : 肺・胸膜の腫瘍. 深山正久, 森永正二郎 他 (編) : 外科病理学 I, 文光堂, 2020, pp305-378
 
3) Suzuki M, Nakatani Y, Ito H et al : Pulmonary adenocarcinoma with high-grade fetal adenocarcinoma component has a poor prognosis, comparable to that of micropapillary adenocarcinoma. Mod Pathol 31 : 1404-1417, 2018
 
4) Nakatani Y, Masudo K, Miyagi Y et al : Aberrant nuclear localization and gene mutation of beta-catenin in lowgrade adenocarcinoma of fetal lung type : up-regulation of the Wnt signaling pathway may be a common denominator for the development of tumors that form morules. Mod Pathol 15 : 617-624, 2002
PubMed
5) Morita S, Yoshida A, Goto A et al : High-grade lung adenocarcinoma with fetal lung-like morphology : clinicopathologic, immunohistochemical, and molecular analyses of 17 cases. Am J Surg Pathol 37 : 924-932, 2013
PubMed
6) Li Y, Xi SY, Yong JJ et al : Morphologic, immunohistochemical, and genetic differences between high-grade and lowgrade fetal adenocarcinomas of the lung. Am J Surg Pathol 45 : 1464-1475, 2021
 
7) Suzuki M, Kasajima R, Yokose T et al : Comprehensive molecular analysis of genomic profiles and PD-L1 expression in lung adenocarcinoma with a high-grade fetal adenocarcinoma component. Transl Lung Cancer Res 10 : 1292-1304, 2021
PubMed
8) Kishikawa S, Hayashi T, Saito T et al : Distinct properties of pure- and mixed-type high-grade fetal lung adenocarcinomas by genetic profiling and transcription factor expression. Virchows Archiv 480 : 609-619, 2022
PubMed
9) 中谷行雄, 太田聡 : 胎児型腺癌 (低, 高悪性度). 深山正久, 野口雅之, 松野吉宏 (編) : 腫瘍病理鑑別診断アトラス 肺癌, 第1版, 文光堂, 2014, pp84-91
 
P.115 掲載の参考文献
1) Jain D, MacMahon H, Nakatani Y et al : Enteric-type adenocarcinoma of the lung. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp83-84
 
2) Tsao MS, Fraser RS : Primary pulmonary adenocarcinoma with enteric differentiation. Cancer 68 : 1754-1757, 1991
PubMed
3) Zhao L, Huang S, Liu J et al : Clinicopathological, radiographic and oncogenic features of primary pulmonary enteric adenocarcinoma in comparison with invasive adenocarcinoma in resection specimens. Medicine (Baltimore) 96 : e8153, 2017
PubMed
4) Li H, Cao W : Pulmonary enteric adenocarcinoma : a literature review. J Thorac Dis 12 : 3217-3226, 2020
 
5) Palmirotta R, Lovero D, D'Oronzo S et al : Pulmonary enteric adenocarcinoma : an overview. Expert Rev Mol Med 22 : e1, 2020
PubMed
6) Matsushima J, Yazawa T, Suzuki M et al : Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma : usefulness of SATB2 and β-catenin immunostaining for differentiation from metastatic colorectal carcinoma. Hum Pathol 64 : 179-185, 2017
 
7) Bian T, Zhao J, Feng J et al : Combination of cadherin-17 and SATB homeobox 2 serves as potential optimal makers for the differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal adenocarcinoma. Oncotarget 8 : 63442-63452, 2017
 
8) Chen M, Liu P, Yan F et al : Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma : implications for differential diagnosis and immunotherapy. J Transl Med 16 : 81, 2018
 
9) Jurmeister P, Vollbrecht C, Behnke A et al : Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options. Lung Cancer 138 : 43-51, 2019
PubMed
10) Zhang J, Xiang C, Han Y et al : Differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal carcinoma with the assistance of next-generation sequencing and immunohistochemistry. J Cancer Res Clin Oncol 145 : 269-279, 2019
 
11) Jurmeister P, Scholer A, Arnold A et al : DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer. Mod Pathol 32 : 855-865, 2019
PubMed
12) Garajova I, Funel N, Fiorentino M et al : MicroRNA profiling of primary pulmonary enteric adenocarcinoma in members from the same family reveals some similarities to pancreatic adenocarcinoma-a step towards personalized therapy. Clin Epigenetics 7 : 129, 2015
PubMed
P.119 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Thoracic Tumors, 5th ed, IARC, Lyon, 2021
 
2) Rekhtman N, Travis WD : Large no more : The journey of pulmonary large cell carcinoma from common to rare entity. J Thorac Oncol 14 : 1125-1127, 2019
PubMed
3) Xiachuan L, Jiangyong Y, Ping Z et al : Clinical characteristics and prognosis pf pulmonary large cell carcinoma : a population-based retrospective study using SEER data. Thorac Cancer 11 : 1522-1532, 2020
 
4) Travis WD, Brambilla E, Nicolson AD et al : The 2015 World Health Organization classification of lung tumors : impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10 : 1243-1260, 2015
 
5) Yatabe Y, Dacic S, Borczuk AC et al : Best Practices recommendations for diagnostic immunohistochemistry in lung cancer. J Thorac Oncol 14 : 377-407, 2019
PubMed
6) Rekhtman N, Tafe LJ, Chaft JE et al : Distinct profile of driver mutations and clinical features in immunomarkerdefined subsets of pulmonary large cell carcinoma. Mod Pathol 26 : 511-522, 2013
PubMed
7) Chan AW, Chau SL, Tong JH et al : The landscape of actionable molecular alterations in immunomaker-defined largecell carcinoma of the lung. J Thorac Oncol 14 : 1213-1222, 2019
 
P.122 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Thoracic Tumours, 5th ed, IARC, Lyon, 2021
 
2) Travis WD, Brambilla E, Noguchi M et al : International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6 : 244-285, 2011
 
3) Ogawa K, Uruga H, Fujii T et al : Characteristics of non-small-cell lung cancer with interstitial pneumonia : variation in cancer location, histopathology, and frequency of postoperative acute exacerbations in interstitial pneumonia. BMC Pulm Med 20 : 307, 2020
PubMed
4) Cooke DT, Nguyen DV, Yang Y et al : Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy. Ann Thorac Surg 90 : 943-948, 2010
PubMed
5) Filosso PL, Ruffini E, Asioli S et al : Adenosquamous lung carcinomas : a histologic subtype with poor prognosis. Lung Cancer 74 : 25-29, 2011
PubMed
6) Maeda H, Matsumura A, Kawabata T et al : Adenosquamous carcinoma of the lung : surgical results as compared with squamous cell and adenocarcinoma cases. Eur J Cardiothorac Surg 41 : 357-361, 2012
PubMed
7) Shiozawa T, Ishii G, Goto K et al : Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung. Pathol Int 63 : 77-84, 2013
PubMed
8) Mordant P, Grand B, Cazes A et al : Adenosquamous carcinoma of the lung : surgical management, pathologic characteristics, and prognostic implications. Ann Thorac Surg 95 : 1189-1195, 2013
PubMed
9) Watanabe Y, Tsuta K, Kusumoto M et al : Clinicopathologic features and computed tomographic findings of 52 surgically resected adenosquamous carcinomas of the lung. Ann Thorac Surg 97 : 245-251, 2014
PubMed
10) Rekhtman N, Paik PK, Arcila ME et al : Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung : Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations. Clin Cancer Res 18 : 1167-1176, 2012
PubMed
11) Rao N : Adenosquamous carcinoma. Semin Diagn Pathol 31 : 271-277, 2014
PubMed
12) Pelosi G, Fabbri A, Tamborini E et al : Challenging Lung Carcinoma with Coexistent ΔNp63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. J Thorac Oncol 10 : 1500-1502, 2015
 
13) Vassella E, Langsch S, Dettmer MS et al : Molecular profiling of lung adenosquamous carcinoma : hybrid or genuine type? Oncotarget 6 : 23905-23916, 2015
PubMed
14) Lin G, Li C, Li PS et al : Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma. Ann Oncol 31 : 517-524, 2020
 
15) Cheng Y, Zhang Y, Yuan Y et al : The Comprehensive Analyses of Genomic Variations and Assessment of TMB and PD-L1 Expression in Chinese Lung Adenosquamous Carcinoma. Front Genet 11 : 609405, 2021
 
16) Shi X, Wu S, Sun J et al : PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer. Sci Rep 7 : 46209, 2017
 
17) Tsuta K, Kawago M, Yoshida A et al : Primary lung adenocarcinoma with morule-like components : A unique histologic hallmark of aggressive behavior and EGFR mutation. Lung Cancer 85 : 12-18, 2014
PubMed
18) Yousem SA : Peripheral squamous cell carcinoma of lung : patterns of growth with particular focus on airspace filling. Hum Pathol 40 : 861-867, 2009
PubMed
19) Roden AC, Garcia JJ, Wehrs RN et al : Histopathologic, immunophenotypic and cytogenetic features of pulmonary mucoepidermoid carcinoma. Mod Pathol 27 : 1479-1488, 2014
PubMed
20) Mather JP, Roberts PE, Pan Z et al : Isolation of cancer stem like cells from human adenosquamous carcinoma of the lung supports a monoclonal origin from a multipotential tissue stem cell. PLoS One 8 : e79456, 2013
PubMed
21) Kong M, Sung J-Y, Lee SH : Osimertinib for Secondary T790M-Mutation Positive Squamous Cell Carcinoma Transformation After Afatinib Failure. J Thorac Oncol 13 : e252-e254, 2018
PubMed
22) Wang Y, Qian F, Hu M et al : Clinical significance of visceral pleural and lymphovascular invasion in surgically resected adenosquamous lung cancer. Eur J Cardiothorac Surg 59 : 617-623, 2020
 
P.129 掲載の参考文献
1) Yang Z, Xu J, Li L et al : Integrated molecular characterization reveals potential therapeutic strategies for pulmonary sarcomatoid carcinoma. Nat Commun 11 : 4878, 2020
 
2) Liu X, Wang F, Xu C et al : Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma. Oncogene 40 : 821-832, 2021
 
3) Schrock AB, Li SD, Frampton GM et al : Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. J Thorac Oncol 12 : 932-942, 2017
PubMed
4) Lococo F, Gandolfi G, Rossi G et al : Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma. J Thorac Oncol 11 : 1282-1292, 2016
PubMed
5) Liu X, Jia Y, Stoopler MB et al : Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. J Clin Oncol 34 : 794-802, 2016
 
6) Nagano M, Kohsaka S, Hayashi T et al : Comprehensive molecular profiling of pulmonary pleomorphic carcinoma. NPJ Precis Oncol 5 : 57, 2021
PubMed
7) Terra S, Roden AC, Aubry MC et al : Utility of Immunohistochemistry for MUC4 and GATA3 to Aid in the Distinction of Pleural Sarcomatoid Mesothelioma From Pulmonary Sarcomatoid Carcinoma. Arch Pathol Lab Med 145 : 208-213, 2021
PubMed
P.132 掲載の参考文献
1) Koss MN, Hochholzer L, O'Leary T : Pulmonary blastomas. Cancer 67 : 2368-2381, 1991
PubMed
2) Nakatani Y, Miyagi Y, Takemura T et al : Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma : beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. Am J Surg Pathol 28 : 921-927, 2004
 
3) de Kock L, Bah I, Brunet J et al : Somatic DICER1 mutations in adult-onset pulmonary blastoma. Eur Respir J 47 : 1879-1882, 2016
PubMed
4) Li Y, Xi SY, Yong JJ et al : Morphologic, Immunohistochemical, and Genetic Differences Between High-grade and Low-grade Fetal Adenocarcinomas of the Lung. Am J Surg Pathol 45 : 1464-1475, 2021
 
5) Nakatani Y, Hiroshima K, Mark EJ : Sarcomatoid carcinomas and variants. in : Hasleton P, Flieder DB (eds) : "Spencer's Pathology of the Lung, 6 ed", Cambridge University Press, 2013
 
6) 中谷行雄, 廣島健三 : Spencerとpulmonary blastoma. 病理と臨床 31 : 454-455, 2013
Medical*Online
P.138 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Thoracic Tumours, 5th ed, IARC, Lyon, 2021
 
2) Yoon JY, Sigel K, Martin J et al : Evaluation of the Prognostic Significance of TNM Staging Guidelines in Lung Carcinoid Tumors. J Thorac Oncol 14 : 184-192, 2019
PubMed
3) Caplin ME, Baudin E, Ferollaet P et al : Pulmonary neuroendocrine (carcinoid) tumors : European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol 26 : 1604-1620, 2015
 
4) Chong CR, Wirth LJ, Nishino M et al : Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer 86 : 241-246, 2014
PubMed
5) Reuling EMBP, Dickhoff C, Plaisier PW et al : Endobronchial and surgical treatment of pulmonary carcinoid tumors : A systematic literature review. Lung Cancer 134 : 85-95, 2019
PubMed
6) 日本肺癌学会 (編) : 肺癌診療ガイドライン, 金原出版, 2020
 
7) Derks JL, Leblay N, Lantuejoul S et al : New Insights into the Molecular Characteristics of Pulmonary Carcinoids and Large Cell Neuroendocrine Carcinomas, and the Impact on Their Clinical Management. J Thorac Oncol 13 : 752-766, 2018
PubMed
P.144 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Thoracic Tumours, 5th ed, IARC, Lyon, 2021
 
2) Derks JL, Leblay N, Lantuejoul S et al : New Insights into the molecular characteristics of pulmonary carcinoids and large cell neuroendocrine carcinomas, and the impact on their clinical management. J Thorac Oncol 13 : 752-766, 2018
PubMed
3) Rekhtman N, Pietanza MC, Hellmann MD et al : Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res 22 : 3618-3629, 2016
PubMed
4) Rossi G, Bertero L, Marchio C et al : Molecular alterations of neuroendocrine tumours of the lung. Histopathology 72 : 142-152, 2018
PubMed
5) George J, Walter V, Peifer M et al : Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nat Commun 13 : 1048, 2018
 
6) Miyoshi T, Umemura S, Matsumura Y et al : Genomic profiling of large-cell neuroendocrine carcinoma of the lung. Clin Cancer Res 23 : 757-765, 2017
PubMed
7) Gazdar AF, Savage TK, Johnson JE et al : The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol 10 : 553-564, 2015
 
8) Gazdar AF, Savage TK, Johnson JE et al : The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol 10 : 553-564, 2015
 
9) Lazaro S, Perez-Crespo M, Lorz C et al : Differential development of large-cell neuroendocrine or small-cell lung carcinoma upon inactivation of 4 tumor suppressor genes. Proc Natl Acad Sci U S A 116 : 22300-22306
 
P.150 掲載の参考文献
1) Mukhopadhyay S, Dermawan JK, Lanigan CP et al : Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms : an immunohistochemical study of 345 cases, including 292 whole-tissue sections. Mod Pathol 32 : 100-109, 2019
PubMed
2) Hanley KZ, Durearu ZJ, Cohen C et al : Orthopedia homeobox is preferentially expressed in typical carcinoids of the lung. Cancer Cytopathol 126 : 236-242, 2018
 
3) Viswanathan K, Borczuk AC, Siddiqui MT : Orthopedia homeobox protein (OTP) is a sensitive and specific marker for primary pulmonary carcinoid tumors in cytologic and surgical specimens. J Am Soc Cytoparhol 8 : 39-46, 2019
PubMed
4) Cui M, Augert A, Rongione M et al : PTEN is a potent suppressor of small cell lung cancer : Mol Cancer Res 12 : 654-659, 2014
PubMed
5) Schaffer BE, Park KS, Yiu G et al : Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res 70 : 3877-3883, 2010
 
6) Rudin CM, Durinck S, Stawiski EW et al : Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44 : 1111-1116, 2012
PubMed
7) George J, Lim JS, Jang SJ et al : Comprehensive genomic profiles of small cell lung cancer. Nature 524 : 47-53, 2015
PubMed
8) Peifer M, Fernandez-Cuesta L, Sos ML et al : Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44 : 1104-1110, 2012
PubMed
9) Gazzeri S, Brambilla E, Jacrot M et al : Activation of myc gene family in human lung carcinomas and during heterotransplantation into nude mice. Cancer Res 51 : 2566-2571, 1991
PubMed
10) Rudin CM, Poirier JT, Byers LA et al : Molecular subtypes of small cell lung cancer : synthesis of human and mouse model data. Nat Rev Cancer 19 : 289-297, 2019
 
11) Ito T, Matsubara D, Tanaka I et al : Loss of YAP1 defines neuroendocrine differentiation of lung Tumors. Cancer Sci 107 : 1527-1538, 2019
 
12) Kawai H, Matsuoka R, Ito T et al : Molecular subtypes of high-grade neuroendocrine carcinoma (HGNEC) : What is YAP1-positive HGNEC? Front Biosci (Landmark Ed) 27 : 108, 2022
PubMed
P.155 掲載の参考文献
1) Travis WD, Nicholson AG, Geisinger KR et al : Tumors of salivary gland type. in : Silverberg SG, DeLellis RA, Sobin LH (eds) : "Tumors of the Lower Respiratory Tract. AFIP Atlas of Tumor Pathology", 4th ed, ARP Press, Arlington, Virginia, 2019, pp339-370
 
2) Husain AN, Farver CF, Nicholson AG : Mucoepidermoid carcinoma of the lung. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp121-122
 
3) Mehrad M, Farver CF, Nicholson AG : Adenoid cystic carcinoma of the lung. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp117-118
 
4) Szymanski LJ, Molas-Torreblanca K, Bawab R et al : Bronchial mucoepidermoid carcinoma with the classic MAML2 gene rearrangement in a 2-year-old boy. Pediatr Dev Pathol 21 : 480-485, 2018
 
5) Fehr A, Werenicz S, Trocchi P et al : Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTC1/3-MAML2 genotyping. Virchows Archiv 479 : 975-985, 2021
PubMed
6) Chan ES, Tong JH, To KF : CRTC3-MAML2 fusion transcript in a bronchial mucoepidermoid carcinoma. Pathology 45 : 698-701, 2013
 
7) Pei J, Flieder DB, Patchefsky A et al : Detecting MYB and MYBL1 fusion genes in tracheobronchial adenoid cystic carcinoma by targeted RNA-sequencing. Mod Pathol 32 : 1416-20, 2019
PubMed
8) Wetterskog D, Wilkerson PM, Rodrigues DN et al : Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. Histopathology 62 : 543-550, 2013
PubMed
P.159 掲載の参考文献
1) Travis WD, Nicholson AG, Geisinger KR et al : Tumors of salivary gland type. in : Silverberg SG, DeLellis RA, Sobin LH (eds) : "Tumors of the Lower Respiratory Tract. AFIP Atlas of Tumor Pathology", 4th ed, ARP Press, Arlington, Virginia, 2019, pp339-370
 
2) Husain AN, Hornick JL : Myoepithelioma and myoepithelial carcinoma of the lung. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp125-126
 
3) Husain AN, Farver CF, Nicholson AG : Hyalinizing clear cell carcinoma of the lung. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic tumours", 5th ed, IARC, Lyon, 2021, pp123-124
 
4) Husain AN, Farver CF, Nicholson AG : Epithelial-myoepithelial carcinoma of the lung. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic tumours", 5th ed, IARC, Lyon, 2021, pp119-120
 
5) Mori M, Hanagiri T, Nakanishi R et al : Primary epithelial-myoepithelial carcinoma of the lung with cavitary lesion : a case report. Mol Clin Oncol 9 : 315-317, 2018
PubMed
6) Leduc C, Zhang L, Oz B et al : Thoracic myoepithelial tumors : a pathologic and molecular study of 8 cases with review of the literature. Am J Surg Pathol 40 : 212-223, 2016
PubMed
7) Takamatsu M, Sato Y, Muto M et al : Hyalinizing clear cell carcinoma of the bronchial glands : presentation of three cases and pathological comparisons with salivary gland counterparts and bronchial mucoepidermoid carcinomas. Mod Pathol 31 : 923-933, 2018
PubMed
8) Antonescu CR, Zhang L, Chang NE et al : EWSR1-POU5F1 fusion in soft tissue myoepithelial tumors. A molecular analysis of sixty-six cases, including soft tissue, bone, and visceral lesions, showing common involvement of the EWSR1 gene. Genes Chromosomes Cancer 49 : 1114-1124, 2010
 
9) Skalova A, Agaimy A, Vanecek T et al : Molecular profiling of clear cell myoepithelial carcinoma of salivary glands with EWSR1 rearrangement identifies frequent PLAG1 gene fusions but no EWSR1 fusion transcripts. Am J Surg Pathol 45 : 1-13, 2021
PubMed
10) Agaimy A, Naroditsky I, Ben-Izhak O : Primary high-grade myoepithelial carcinoma of the lung : A study of three cases illustrating frequent SMARCB1-deficiency and review of the literature. Ann Diagn Pathol 53 : 151759, 2021
 
11) Yanagawa N, Sato A, Nishiya M et al : Pulmonary epithelial-myoepithelial carcinoma without AKT1, HRAS or PIK-3CA mutations : a case report. Diagn Pathol 15 : 105, 2020
PubMed
P.163 掲載の参考文献
1) Shiota H, Elya JE, Alekseyenko AA et al : "Z4" Complex Member Fusions in NUT Carcinoma : Implications for a Novel Oncogenic Mechanism. Mol Cancer Res 16 : 1826-1833. 2018
PubMed
2) Chau NG, Ma C, Danga K et al : An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma : Analysis of 124 Patients. JNCI Cancer Spectr 4 : pkz094, 2019
PubMed
3) Stevens TM, Morlote D, Xiu J et al : NUTM1-rearranged neoplasia : a multi-institution experience yields novel fusion partners and expands the histologic spectrum. Mod Pathol 32 : 764-773, 2019
PubMed
4) Bauer DE, Mitchell CM, Strait KM et al : Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 18 : 5773-5779, 2012
PubMed
5) Storck S, Kennedy AL, Marcus KJ et al : Pediatric NUTmidline carcinoma : Therapeutic success employing a sarcoma based multimodal approach. Pediatr Hematol Oncol 34 : 231-237, 2017
PubMed
6) Clinical Trials. gov Internet. Bethesda (MD) : U.S. National Library of Medicine ; 2020. Identifier NCT02516553, BI 894999 First in human dose finding study in advanced malignancies ; first posted 2015 Aug 6 updated 2020 Aug 12. Available from : https://clinicaltrials.gov/ct2/show/NCT02516553
 
7) Tanaka M, Kato K, Gomi K et al : NUT midline carcinoma : report of 2 cases suggestive of pulmonary origin. Am J Surg Pathol 36 : 381-388, 2012
PubMed
8) Bishop JA, French CA, Ali SZ : Cytopathologic features of NUT midline carcinoma : A series of 26 specimens from 13 patients. Cancer Cytopathol 124 : 901-908, 2016
PubMed
9) Haack H, Johnson LA, Fry CJ et al : Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol 33 : 984-991, 2009
PubMed
10) Matsuda K, Kashima J, Yatabe Y : The Isoform Matters in NUT Carcinoma : A Diagnostic Pitfall of p40 Immunohistochemistry. J Thorac Oncol 15 : e176-e178, 2020
PubMed
11) Lee JK, Louzada S, An Y et al : Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma. Ann Oncol 28 : 890-897, 2017
PubMed
P.166 掲載の参考文献
1) Le Loarer F, Watson S, Pierron G et al : SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet 47 : 1200-1205, 2015
PubMed
2) Yoshida A, Kobayashi E, Kubo T et al : Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol 30 : 797-809, 2017
PubMed
3) Rekhtman N, Montecalvo J, Chang JC et al : SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. J Thorac Oncol 15 : 231-247, 2020
PubMed
4) Karnezis AN, Hoang LN, Coatham M et al : Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. Mod Pathol 29 : 302-314, 2016
PubMed
5) Agaimy A, Daum O, Markl B et al : SWI/SNF Complexdeficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract : A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2. Am J Surg Pathol 40 : 544-553, 2016
PubMed
6) Dagogo-Jack I, Schrock AB, Kem M et al : Clinicopathologic Characteristics of BRG1-Deficient NSCLC. J Thorac Oncol 15 : 766-776, 2020
PubMed
P.174 掲載の参考文献
1) Boland JM, Aubry MC : Pulmonary hamartoma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp154-155
 
2) Fiorelli A, D'Andrilli A, Carlucci A et al : Pulmonary Hamartoma Associated With Lung Cancer (PHALC Study) : Results of a Multicenter Study. Lung 199 : 369-378, 2021
PubMed
3) van den Bosch JM, Wagenaar SS, Corrin B et al : Mesenchymoma of the lung (so called hamartoma) : a review of 154 parenchymal and endobronchial cases. Thorax 42 : 790-793, 1987
PubMed
4) Rodriguez FJ, Aubry MC, Tazelaar HD et al : Pulmonary chondroma : a tumor associated with Carney triad and different from pulmonary hamartoma. Am J Surg Pathol 31 : 1844-1853, 2007
PubMed
5) Hansen CP, Holtveg H, Francis D et al : Pulmonary hamartoma. J Thorac Cardiovasc Surg 104 : 674-678, 1992
PubMed
6) Chatzopoulos K, Johnson TF, Boland JM : Clinical, Radiologic, and Pathologic Characteristics of Pulmonary Hamartomas With Uncommon Presentation. Am J Clin Pathol 155 : 903-911, 2021
PubMed
7) Cosio BG, Villena V, Echave-Sustaeta J et al : Endobronchial hamartoma. Chest 122 : 202-205, 2002
PubMed
8) Trahan S, Erickson-Johnson MR, Rodriguez F et al : Formation of the 12q14-q15 amplicon precedes the development of a well-differentiated liposarcoma arising from a nonchondroid pulmonary hamartoma. Am J Surg Pathol 30 : 1326-1329, 2006
PubMed
9) Basile A, Gregoris A, Antoci B et al : Malignant change in a benign pulmonary hamartoma. Thorax 44 : 232-233, 1989
 
10) Chatzopoulos K, Fritchie KJ, Aubry MC et al : Loss of succinate dehydrogenase B immunohistochemical expression distinguishes pulmonary chondromas from hamartomas. Histopathology 75 : 825-832, 2019
PubMed
11) Hochhegger B, Nin CS, Alves GRT et al : Multidetector Computed Tomography Findings in Pulmonary Hamartomas : A New Fat Detection Threshold. J Thorac Imaging 31 : 11-14, 2016
PubMed
12) Gleeson T, Thiessen R, Hannigan A et al : Pulmonary hamartomas : CT pixel analysis for fat attenuation using radiologic-pathologic correlation. J Med Imaging Radiat Oncol 57 : 534-543, 2013
PubMed
13) Jiang L, Huang Y, Tang Q et al : 18F-FDG PET/CT characteristics of pulmonary sclerosing hemangioma vs. pulmonary hamartoma. Oncol Lett 16 : 660-665, 2018
 
14) Rossi G, Cavazza A, Comin C et al : Mucinous Adenomyomatous Pulmonary Hamartoma : Clinicopathologic, Immunohistochemical, and Molecular Features of 6 Cases. Int J Surg Pathol 29 : 273-280, 2021
PubMed
15) Dal Cin P, Kools P, De Jonge I et al : Rearrangement of 12q14-15 in pulmonary chondroid hamartoma. Genes Chromosomes Cancer 8 : 131-133, 1993
PubMed
16) Xiao S, Lux ML, Reeves R et al : HMGI (Y) activation by chromosome 6p21 rearrangements in multilineage mesenchymal cells from pulmonary hamartoma. Am J Pathol 150 : 901-910, 1997
PubMed
17) Johansson M, Dietrich C, Mandahl N et al : Recombinations of chromosomal bands 6p21 and 14q24 characterise pulmonary hamartomas. Br J Cancer 67 : 1236-1241, 1993
PubMed
18) Johansson M, Heim S, Mandahl N et al : t (3 ; 6 ; 14) (p21 ; p21 ; q24) as the sole clonal chromosome abnormality in a hamartoma of the lung. Cancer Genet Cytogenet 60 : 219-220, 1992
 
19) Kazmierczak B, Wanschura S, Rommel B et al : Ten pulmonary chondroid hamartomas with chromosome 6p21 breakpoints within the HMG-I (Y) gene or its immediate surroundings. J Natl Cancer Inst 88 : 1234-1236, 1996
PubMed
20) Rogalla P, Lemke I, Kazmierczak B et al : An identical HMGIC-LPP fusion transcript is consistently expressed in pulmonary chondroid hamartomas with t (3 ; 12) (q27-28 ; q14-15). Genes Chromosomes Cancer 29 : 363-366, 2000
 
21) von Ahsen I, Rogalla P, Bullerdiek J : Expression patterns of the LPP-HMGA2 fusion transcript in pulmonary chondroid hamartomas with t (3 ; 12) (q27-28 ; q14-15). Cancer Genet Cytogenet 163 : 68-70, 2005
 
22) Schoenmakers EF, Wanschura S, Mols R et al : Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat Genet 10 : 436-444, 1995
PubMed
23) Fletcher JA, Longtine J, Wallace K et al : Cytogenetic and histologic findings in 17 pulmonary chondroid hamartomas : evidence for a pathogenetic relationship with lipomas and leiomyomas. Genes Chromosomes Cancer 12 : 220-223, 1995
PubMed
24) Schoenmakers EF, Kools PF, Mols R et al : Physical mapping of chromosome 12q breakpoints in lipoma, pleomorphic salivary gland adenoma, uterine leiomyoma, and myxoid liposarcoma. Genomics 20 : 210-222, 1994
PubMed
25) Williams AJ, Powell WL, Collins T et al : HMGI (Y) expression in human uterine leiomyomata. Involvement of another high-mobility group architectural factor in a benign neoplasm. Am J Pathol 150 : 911-918, 1997
 
26) Boland JM, Fritchie KJ, Erickson-Johnson MR et al : Endobronchial lipomatous tumors : clinicopathologic analysis of 12 cases with molecular cytogenetic evidence supporting classification as "lipoma". Am J Surg Pathol 37 : 1715-1721, 2013
PubMed
27) Aubry MC, Boland JM : Pulmonary chondroma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp156-157
 
28) Carney JA, Sheps SG, Go VL et al : The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med 296 : 1517-1518, 1977
PubMed
29) Carney JA : Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad) : natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 74 : 543-552, 1999
PubMed
30) Rodriguez FJ, Aubry MC, Tazelaar HD et al : Pulmonary chondroma : a tumor associated with Carney triad and different from pulmonary hamartoma. Am J Surg Pathol 31 : 1844-1853, 2007
PubMed
31) Tian D, Wen H, Zhou Y et al : Pulmonary chondroma : A clinicopathological study of 29 cases and a review of the literature. Mol Clin Oncol 5 : 211-215, 2016
 
32) Gill AJ : Succinate dehydrogenase (SDH) -deficient neoplasia. Histopathology 72 : 106-116, 2018
PubMed
33) Haller F, Moskalev EA, Faucz FR et al : Aberrant DNA hypermethylation of SDHC : a novel mechanism of tumor development in Carney triad. Endocr Relat Cancer 21 : 567-77, 2014
PubMed
34) Killian JK, Miettinen M, Walker RL et al : Recurrent epimutation of SDHC in gastrointestinal stromal tumors. Sci Transl Med 6 : 268ra177, 2014
PubMed
35) Matyakhina L, Bei TA, McWhinney SR et al : Genetics of carney triad : recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. J Clin Endocrinol Metab 92 : 2938-2943, 2007
PubMed
36) Kalhor N, Suster S, Moran CA : Primary pulmonary chondrosarcomas : a clinicopathologic study of 4 cases. Hum Pathol 42 : 1629-1634, 2011
PubMed
37) Yi ES, Calonje JE : Diffuse pulmonary lymphangiomatosis. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp158-159
 
38) International Society for the Study of Vascular Anomalies : ISSVA classification for vascular anomalies. https://www.issva.org/UserFiles/file/ISSVA-Classification-2018.pdf
 
39) Tazelaar HD, Kerr D, Yousem SA et al : Diffuse pulmonary lymphangiomatosis. Hum Pathol 24 : 1313-1322, 1993
PubMed
40) Yu W, Mi L, Cong J et al : Diffuse pulmonary lymphangiomatosis : A rare case report in an adult. Medicine (Baltimore) 98 : e17349, 2019
 
41) Boland JM, Tazelaar HD, Colby TV et al : Diffuse pulmonary lymphatic disease presenting as interstitial lung disease in adulthood : report of 3 cases. Am J Surg Pathol 36 : 1548-1554, 2012
PubMed
42) Alvarez OA, Kjellin I, Zuppan CW : Thoracic lymphangiomatosis in a child. J Pediatr Hematol Oncol 26 : 136-141, 2004
 
43) Faul JL, Berry GJ, Colby TV et al : Thoracic lymphangiomas, lymphangiectasis, lymphangiomatosis, and lymphatic dysplasia syndrome. Am J Respir Crit Care Med 161 : 1037-1046, 2000
PubMed
44) Ozeki M, Fukao T. Generalized Lymphatic Anomaly and Gorham-Stout Disease : Overview and Recent Insights. Adv Wound Care (New Rochelle) 8 : 230-245, 2019
PubMed
45) Dietz Jr WH, Stuart MJ : Splenic consumptive coagulopathy in a patient with disseminated lymphangiomatosis. J Pediatr 90 : 421-423, 1977
 
46) Hajj LE, Mazieres J, Rouquette I et al : Diagnostic value of bronchoscopy, CT and transbronchial biopsies in diffuse pulmonary lymphangiomatosis : case report and review of the literature. Clin Radiol 60 : 921-925, 2005
 
47) Kadakia KC, Patel SM, Yi ES et al : Diffuse pulmonary lymphangiomatosis. Can Respir J 20 : 52-54, 2013
PubMed
48) Kandil A, Rostom AY, Mourad WA et al : Successful control of extensive thoracic lymphangiomatosis by irradiation. Clin Oncol 9 : 407-411, 1997
PubMed
49) Ozeki M, Funato M, Kanda K et al : Clinical improvement of diffuse lymphangiomatosis with pegylated interferon alfa-2b therapy : case report and review of the literature. Pediatr Hematol Oncol 24 : 513-524, 2007
PubMed
50) Ozeki M, Fukao T, Kondo N : Propranolol for intractable diffuse lymphangiomatosis. N Engl J Med 364 : 1380-1382, 2011
PubMed
51) Hangul M, Kose M, Ozcan A et al : Propranolol treatment for chylothorax due to diffuse lymphangiomatosis. Pediatr Blood Cancer 66 : e27592, 2019
PubMed
52) Aman J, Thunnissen E, Paul MA et al : Successful treatment of diffuse pulmonary lymphangiomatosis with bevacizumab. Ann Intern Med 156 : 839-840, 2012
PubMed
53) Onyeforo E, Barnett A, Zagami D et al : Diffuse pulmonary lymphangiomatosis treated with bevacizumab. Respirol Case Rep 7 : e00384, 2018
PubMed
54) Maurac A, Debray MP, Crestani B et al : Thoracic involvement of diffuse lymphangiomatosis successfully treated with sildenafil. BMJ Case Rep 12 : e228523, 2019
PubMed
55) Adams DM, Trenor 3rd CC, Hammill AM et al : Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics 137 : e20153257, 2016
 
56) Wiegand S, Wichmann G, Dietz A : Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus : A Systematic Review. Lymphat Res Biol 16 : 330-339, 2018
PubMed
57) Ozeki M, Nozawa A, Yasue S et al : The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies. Orphanet J Rare Dis 14 : 141, 2019
 
58) Kinnier CV, Eu JPC, Davis RD et al : Successful bilateral lung transplantation for lymphangiomatosis. Am J Transplant 8 : 1946-1950, 2008
PubMed
59) Swensen SJ, Hartman TE, Mayo JR et al : Diffuse pulmonary lymphangiomatosis : CT findings. J Comput Assist Tomogr 19 : 348-352, 1995
 
60) Yekeler E, Dursun M, Yildirim A et al : Diffuse pulmonary lymphangiomatosis : imaging findings. Diagn Interv Radiol 11 : 31-34, 2005
PubMed
61) Raman SP, Pipavath SNJ, Raghu G et al : Imaging of thoracic lymphatic diseases. AJR Am J Roentgenol 193 : 1504-1513, 2009
PubMed
62) Sun X, Shen W, Xia S et al : Diffuse Pulmonary Lymphangiomatosis : MDCT Findings After Direct Lymphangiography. AJR Am J Roentgenol 208 : 300-305, 2017
PubMed
63) Kelso JM, Kerr DJ, Lie JT et al : Unusual diffuse pulmonary lymphatic proliferation in a young boy. Chest 100 : 556-560, 1991
 
64) Manevitz-Mendelson E, Leichner GS, Barel O et al : Somatic NRAS mutation in patient with generalized lymphatic anomaly. Angiogenesis 21 : 287-298, 2018
PubMed
65) Patel RM, Goldblum JR, Hsi ED : Immunohistochemical detection of human herpes virus-8 latent nuclear antigen-1 is useful in the diagnosis of Kaposi sarcoma. Mod Pathol 17 : 456-460, 2004
PubMed
66) Lyons LL, North PE, Mac-Moune Lai F et al : Kaposiform hemangioendothelioma : a study of 33 cases emphasizing its pathologic, immunophenotypic, and biologic uniqueness from juvenile hemangioma. Am J Surg Pathol 28 : 559-568, 2004
PubMed
67) Ji Y, Chen S, Peng S et al : Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma : similarities and differences. Orphanet J Rare Dis 14 : 165, 2019
 
68) Le Cras TD, Mobberley-Schuman PS, Broering M et al : Angiopoietins as serum biomarkers for lymphatic anomalies. Angiogenesis 20 : 163-173, 2017
PubMed
P.182 掲載の参考文献
1) Messinger YH, Stewart DR, Priest JR et al : Pleuropulmonary blastoma : a report on 350 central pathology-confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry. Cancer 121 : 276-285, 2015
PubMed
2) Hill DA, Jarzembowski JA, Priest JR et al : Type I pleuropulmonary blastoma : pathology and biology study of 51 cases from the international pleuropulmonary blastoma registry. Am J Surg Pathol 32 : 282-295, 2008
PubMed
3) Gonzalez IA, Mallinger P, Watson D et al : Expression of p53 is significantly associated with recurrence-free survival and overall sur vival in pleuropulmonary blastoma (PPB) : a report from the International Pleuropulmonary Blastoma/DICER1 Registry. Mod Pathol 34 : 1104-1115, 2021
 
4) Pugh TJ, Yu W, Yang J et al : Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences. Oncogene 33 : 5295-5302, 2014
 
5) Brenneman M, Field A, Yang J et al : Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in pleuropulmonary blastoma/DICER1 syndrome : a unique variant of the two-hit tumor suppression model. F1000Res 4 : 214, 2015
PubMed
6) Assi T, Kattan J, Rassy E et al : A comprehensive review on the diagnosis and management of intimal sarcoma of the pulmonary artery. Crit Rev Oncol Hematol 147 : 102889, 2020
PubMed
7) Bode-Lesniewska B, Zhao J, Speel EJ et al : Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery. Virchows Arch 438 : 57-65, 2001
PubMed
8) Dewaele B, Floris G, Finalet-Ferreiro J et al : Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma. Cancer Res 70 : 7304-7314, 2010
PubMed
9) Tamborini E, Casieri P, Miselli F et al : Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. J Pathol 212 : 227-235, 2007
PubMed
10) Agaimy A, Duell T, Morresi-Hauf AT : EWSR1-fusion-negative, SMARCB1-deficient primary pulmonary myxoid sarcoma. Pol J Pathol 68 : 261-267, 2017
PubMed
P.190 掲載の参考文献
1) Jain D, Hornick JL : Lymphangioleiomyomatosis of the lung. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp170-171
 
2) 呼吸器系疾患調査研究班 : リンパ脈管筋腫症 (LAM) (指定難病89). 公益財団法人難病医学研究財団難病情報センター, 東京, 2021 https://www.nanbyou.or.jp/entry/339
 
3) Harknett EC, Chang WYC, Byrnes S et al : Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM 104 : 971-979, 2011
PubMed
4) Ryu JH, Moss J, Beck GJ et al : The NHLBI lymphangioleiomyomatosis registry : characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 173 : 105-111, 2006
PubMed
5) Oprescu N, McCormack FX, Byrnes S et al : Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis : a population-based registry. Lung 191 : 35-42, 2013
PubMed
6) Aubry MC, Myers JL, Ryu JH et al : Pulmonary lymphangioleiomyomatosis in a man. Am J Respir Crit Care Med 162 : 749-752, 2000
 
7) Urban T, Lazor R, Lacronique J et al : Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 78 : 321-337, 1999
 
8) Cudzilo CJ, Szczesniak RD, Brody AS et al : Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest 144 : 578-585, 2013
PubMed
9) Chu SC, Horiba K, Usuki J et al : Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 115 : 1041-1052, 1999
PubMed
10) Matsui K, Tatsuguchi A, Valencia J et al : Extrapulmonary lymphangioleiomyomatosis (LAM) : clinicopathologic features in 22 cases. Hum Pathol 31 : 1242-1248, 2000
PubMed
11) Taveira-DaSilva AM, Johnson SR, Julien-Williams P et al : Pregnancy in lymphangioleiomyomatosis : clinical and lung function outcomes in two national cohorts. Thorax 75 : 904-907, 2020
PubMed
12) McCormack FX, Gupta N, Finlay GR et al : Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines : Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med 194 : 748-761, 2016
 
13) Hirose M, Matsumuro A, Arai T et al : Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. PLoS One 14 : e0212776, 2019
PubMed
14) Steagall WK, Stylianou M, Pacheco-Rodriguez G et al : Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis. JCI Insight 4 : e126703, 2019
PubMed
15) Glasgow CG, Pacheco-Rodriguez G, Steagall WK et al : CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis. Chest 153 : 339-348, 2018
PubMed
16) Gupta N, Finlay GA, Kotloff RM et al : Lymphangioleiomyomatosis Diagnosis and Management : High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. Am J Respir Crit Care Med 196 : 1337-1348, 2017
 
17) Wang Q, Luo M, Xiang B et al : The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis. Respir Res 21 : 55, 2020
PubMed
18) Maisel K, Merrilees MJ, Atochina-Vasserman EN et al : Immune Checkpoint Ligand PD-L1 Is Upregulated in Pulmonary Lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 59 : 723-732, 2018
PubMed
19) Liu HJ, Krymskaya VP, Henske EP : Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis : Progress and Future Directions. Chest 156 : 1062-1067, 2019
PubMed
20) Han F, Dellacecca ER, Barse LW et al : Adoptive T-Cell Transfer to Treat Lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 62 : 793-804, 2020
PubMed
21) Song X, Cai H, Yang C et al : Possible Novel Therapeutic Targets in Lymphangioleiomyomatosis Treatment. Front Med (Lausanne) 7 : 554134, 2020
PubMed
22) Gupta N, Lee HS, Ryu JH et al : The NHLBI LAM Registry : Prognostic Physiologic and Radiologic Biomarkers Emerge From a 15-Year Prospective Longitudinal Analysis. Chest 155 : 288-296, 2019
PubMed
23) Johnson SR, Whale CI, Hubbard RB et al : Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 59 : 800-803, 2004
PubMed
24) Krueger DA, Northrup H, International Tuberous Sclerosis Complex Consensus Group : Tuberous sclerosis complex surveillance and management : recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 49 : 255-265, 2013
 
25) Johnson SR, Cordier JF, Lazor R et al : European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 35 : 14-26, 2010
PubMed
26) Avila NA, Dwyer AJ, Rabel A et al : Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis : comparison of CT features. Radiology 242 : 277-285, 2007
PubMed
27) Adriaensen MEAPM, Schaefer-Prokop CM, Duyndam DAC et al : Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex. Clin Radiol 66 : 625-628, 2011
PubMed
28) Welter S, Thrull P, Westhoff M et al : Difficult diagnosis and rare morphology of lymphangioleiomyomatosis with giant cysts. Respir Med Case Rep 28 : 100873, 2019
PubMed
29) Hou G, Jiang Y, Xu W et al : 68Ga-NOTA-Evans Blue PET/CT findings in lymphangioleiomyomatosis compared with 99mTC-ASC lymphoscintigraphy : a prospective study. Orphanet J Rare Dis 16 : 279, 2021
 
30) Katzenstein AA : Pulmonary lymphangioleiomyomatosis. in Katzenstein AA (ed) : "Katzenstein and Askin's Surgical Pathology of Non-neoplastic Lung Disease", 4th ed, vol. 13, major problems in pathology series. Saunders, Philadelphia, 2006, pp426-430
 
31) Matsui K, Beasley MB, Nelson WK et al : Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol 25 : 479-484, 2001
PubMed
32) Grzegorek I, Lenze D, Chabowski M et al : Immunohistochemical evaluation of pulmonary lymphangioleiomyomatosis. Anticancer Res 35 : 3353-3360, 2015
PubMed
33) Davis JM, Hyjek E, Husain AN et al : Lymphatic endothelial differentiation in pulmonary lymphangioleiomyomatosis cells. J Histochem Cytochem 61 : 580-590, 2013
 
34) Flavin RJ, Cook J, Fiorentino M et al : β-Catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis. Am J Clin Pathol 135 : 776-782, 2011
 
35) Evans JF, Obraztsova K, Lin SM et al : CrossTORC and WNTegration in Disease : Focus on Lymphangioleiomyomatosis. Int J Mol Sci 22 : 223, 2021
 
36) Chilosi M, Pea M, Martignoni G et al : Cathepsin-K expression in pulmonary lymphangioleiomyomatosis. Mod Pathol 22 : 161-166, 2009
PubMed
37) Lam HC, Nijmeh J, Henske EP : New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex. J Pathol 241 : 219-225, 2017
PubMed
38) Carsillo T, Astrinidis A, Henske EP : Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 97 : 6085-6090, 2000
PubMed
39) Yu J, Astrinidis A, Henske EP : Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med 164 : 1537-1540, 2001
PubMed
40) Terasaki Y, Yahiro K, Pacheco-Rodriguez G et al : Effects of prolactin on TSC2-null Eker rat cells and in pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med 182 : 531-539, 2010
PubMed
41) Alkharusi A, Lesma E, Ancona S et al : Role of Prolactin Receptors in Lymphangioleiomyomatosis. PLoS One 11 : e0146653, 2016
PubMed
42) Kim W, Giannikou K, Dreier JR et al : A genome-wide association study implicates NR2F2 in lymphangioleiomyomatosis pathogenesis. Eur Respir J 53 : 1900329, 2019
PubMed
43) Karbowniczek M, Astrinidis A, Balsara BR et al : Recurrent lymphangiomyomatosis after transplantation : genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 167 : 976-982, 2003
PubMed
44) Crooks DM, Pacheco-Rodriguez G, DeCastro RM et al : Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 101 : 17462-17467, 2004
PubMed
45) Cai X, Pacheco-Rodriguez G, Fan QY et al : Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med 182 : 1410-1418, 2010
PubMed
46) Henske EP : Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 38 : 376-381, 2003
PubMed
47) Dongre A, Clements D, Fisher AJ et al : Cathepsin K in Lymphangioleiomyomatosis : LAM Cell-Fibroblast Interactions Enhance Protease Activity by Extracellular Acidification. Am J Pathol 187 : 1750-1762, 2017
PubMed
48) Matsui K, Takeda K, Yu ZX et al : Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 124 : 267-275, 2000
PubMed
49) JainD, Doyle LA : PEComa of the lung. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp172-173
 
50) Doyle LA, Argani P, Hornick JL : PEComa. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Soft Tissue and Bone Tumours", 5th ed, IARC, Lyon, 2020, pp312-314
 
51) Hornick JL, Miettinen M, Sciot R et al : PEComa, including angiomyolipoma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Digestive System Tumours", 5th ed, IARC, Lyon, 2019, pp485-487
 
52) Bennett JA, Schoolmeester JK : Perivascular epithelioid cell tumor (PEComa). in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Female Genital Tumours", 5th ed, IARC, Lyon, 2020, pp296-297
 
53) Liebow AA, Castleman B : Benign clear cell ("sugar") tumors of the lung. Yale J Biol Med 43 : 213-222, 1971
PubMed
54) Kung M, Landa JF, Lubin J : Benign clear cell tumor ("ugar tumor") of the trachea. Cancer 54 : 517-519, 1984
 
55) Flieder DB, Travis WD : Clear cell "sugar" tumor of the lung : association with lymphangioleiomyomatosis and multifocal micronodular pneumocyte hyperplasia in a patient with tuberous sclerosis. Am J Surg Pathol 21 : 1242-1247, 1997
 
56) Wang GX, Zhang D, Diao XW et al : Clear cell tumor of the lung : a case report and literature review. World J Surg Oncol 11 : 247, 2013
PubMed
57) Kim WJ, Kim SR, Choe YH et al : Clear cell "sugar" tumor of the lung : a well-enhanced mass with an early washout pattern on dynamic contrast-enhanced computed tomography. J Korean Med Sci 23 : 1121-1124, 2008
 
58) Chen YB, Guo LC, Huang JA et al : Clear cell tumor of the lung : a retrospective analysis. Am J Med Sci 347 : 50-53, 2014
PubMed
59) Gaffey MJ, Mills SE, Askin FB et al : Clear cell tumor of the lung. A clinicopathologic, immunohistochemical, and ultrastructural study of eight cases. Am J Surg Pathol 14 : 248-259, 1990
PubMed
60) Sale GF, Kulander BG : Benign clear cell tumor of lung with necrosis. Cancer 37 : 2355-2358, 1976
PubMed
61) Kavunkal AM, Pandiyan MS, Philip MA et al : Large clear cell tumor of the lung mimicking malignant behavior. Ann Thorac Surg 83 : 310-312, 2007
PubMed
62) Andrion A, Mazzucco G, Gugliotta P et al : Benign clear cell (sugar) tumor of the lung. A light microscopic, histochemical, and ultrastructural study with a review of the literature. Cancer 56 : 2657-2663, 1985
 
63) 三浦一真, 森田純二, 吉澤潔 他 : 肺のBenign clear cell tumorの1例. -本邦報告14例の検討-. 日呼外会誌 7 : 95-101, 1993
 
64) Cavazza A, Sgarbi G, Ferrari G et al : Clear-cell tumor of the lung : description of a case 1 mm in diameter ("microsugar tumor"). Pathologica 93 : 556-560, 2001
PubMed
65) Papla B, Demczuk S, Malinowski E : Benign clear-cell "sugar" tumor of the lung--a case report. Pol J Pathol 54 : 183-185, 2003
 
66) Santana ANC, Nunes FS, Ho N et al : A rare cause of hemoptysis : benign sugar (clear) cell tumor of the lung. Eur J Cardiothorac Surg 25 : 652-654, 2004
 
67) Tsilimigras DI, Bakopoulos A, Ntanasis-Stathopoulos I et al : Clear cell "sugar tumor" of the lung : Diagnostic features of a rare pulmonary tumor. Respir Med Case Rep 23 : 52-54, 2017
PubMed
68) Page S, Yong MS, Sinha A et al : Clear cell sugar tumour : a rare tumour of the lung. ANZ J Surg 90 : E54-E56, 2020
PubMed
69) Chakrabarti A, Bandyopadhyay M, Purkayastha B : Malignant perivascular epitheloid cell tumour (PEComa) of the lung-a rare entity. Innov Surg Sci 2 : 39-42, 2017
 
70) Sale GE, Kulander BG : 'Benign' clear-cell tumor (sugar tumor) of the lung with hepatic metastases ten years after resection of pulmonary primary tumor. Arch Pathol Lab Med 112 : 1177-1178, 1988
PubMed
71) Lawson K, Maher TM, Hansell DM et al : Successful treatment of progressive diffuse PEComatosis. Eur Respir J 40 : 1578-1580, 2012
PubMed
72) Zarbis N, Barth TFE, Blumstein NM et al : Pecoma of the lung : a benign tumor with extensive 18F-2-deoxy-D-glucose uptake. Interact Cardiovasc Thorac Surg 6 : 676-678, 2007
 
73) Becker NH, Soifer I : Benign clear cell tumor ("sugar tumor") of the lung. Cancer 27 : 712-719, 1971
PubMed
74) Hoch WS, Patchefsky AS, Takeda M et al : Benign clear cell tumor of the lung. An ultrastructural study. Cancer 33 : 1328-1336, 1974
PubMed
75) Gaffey MJ, Mills SE, Zarbo RJ et al : Clear cell tumor of the lung. Immunohistochemical and ultrastructural evidence of melanogenesis. Am J Surg Pathol 15 : 644-653, 1991
PubMed
76) Pileri SA, Cavazza A, Schiavina M et al : Clear-cell proliferation of the lung with lymphangioleiomyomatosis-like change. Histopathology 44 : 156-163, 2004.
PubMed
77) Gal AA, Koss MN, Hochholzer L et al : An immunohistochemical study of benign clear cell ('sugar') tumor of the lung. Arch Pathol Lab Med 115 : 1034-1038, 1991
PubMed
78) Hashimoto T, Oka K, Hakozaki H et al : Benign clear cell tumor of the lung. Ultrastruct Pathol 25 : 479-483, 2001
PubMed
79) Bonetti F, Pea M, Martignoni G et al : Clear cell ("sugar") tumor of the lung is a lesion strictly related to angiomyolipoma--the concept of a family of lesions characterized by the presence of the perivascular epithelioid cells (PEC). Pathology 26 : 230-236, 1994
PubMed
80) Adachi Y, Kitamura Y, Nakamura H et al : Benign clear (sugar) cell tumor of the lung with CD1a expression. Pathol Int 56 : 453-456, 2006
PubMed
81) Calio A, Mengoli MC, Cavazza A et al : Cathepsin K expression in clear cell "sugar" tumor (PEComa) of the lung. Virchows Arch 473 : 55-59, 2018.
PubMed
82) Rao Q, Shen Q, Xia QY et al : PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers : clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity. Am J Surg Pathol 39 : 1181-1196, 2015
PubMed
83) Agaram NP, Sung YS, Zhang L et al : Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications. Am J Surg Pathol 39 : 813-825, 2015
PubMed
P.200 掲載の参考文献
1) Takeuchi K, Soda M, Togashi Y et al : Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK : reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. Clin Cancer Res 17 : 3341-3348, 2011
PubMed
2) Yamamoto H, Yoshida A, Taguchi K et al : ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. Histopathology 69 : 72-83, 2016
PubMed
3) Marino-Enriquez A, Wang WL, Roy A et al : Epithelioid inflammatory myofibroblastic sarcoma : An aggressive intra-abdominal variant of inflammatory myofibroblastic tumor with nuclear membrane or perinuclear ALK. Am J Surg Pathol 35 : 135-144, 2011
PubMed
4) Lazar AJ, Tuvin D, Hajibashi S et al : Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 173 : 1518-1527, 2008
PubMed
5) Yamada Y, Hirata M, Sakamoto A et al : A comparison of the usefulness of nuclear beta-catenin in the diagnosis of desmoid-type fibromatosis among commonly used antibeta-catenin antibodies. Pathol Int 71 : 392-399, 2021
 
6) Crago AM, Chmielecki J, Rosenberg M et al : Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysis. Genes Chromosomes Cancer 54 : 606-615, 2015
PubMed
7) Fusco N, Guerini-Rocco E, Augello C et al : Recurrent NAB2-STAT6 gene fusions and oestrogen receptor-alpha expression in pulmonary adenofibromas. Histopathology 70 : 906-917, 2017
PubMed
8) Demicco EG, Wagner MJ, Maki RG et al : Risk assessment in solitary fibrous tumors : validation and refinement of a risk stratification model. Mod Pathol 30 : 1433-1442, 2017
PubMed
9) Reisenauer JS, Mneimneh W, Jenkins S et al : Comparison of Risk Stratification Models to Predict Recurrence and Survival in Pleuropulmonary Solitary Fibrous Tumor. J Thorac Oncol 13 : 1349-1362, 2018
PubMed
10) Salas S, Resseguier N, Blay JY et al : Prediction of local and metastatic recurrence in solitary fibrous tumor : construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. Ann Oncol 28 : 1979-1987, 2017
 
11) Tapias LF, Mino-Kenudson M, Lee H et al : Risk factor analysis for the recurrence of resected solitary fibrous tumours of the pleura : a 33-year experience and proposal for a scoring system. Eur J Cardiothorac Surg 44 : 111-117, 2013
PubMed
12) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Thoracic Tumours, 5th ed, IARC, Lyon, 2021
 
13) Yoshida A, Tsuta K, Ohno M et al : STAT6 immunohistochemistry is helpful in the diagnosis of solitary fibrous tumors. Am J Surg Pathol 38 : 552-559, 2014
PubMed
14) Akaike K, Kurisaki-Arakawa A, Hara K et al : Distinct clinicopathological features of NAB2-STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential. Hum Pathol 46 : 347-356, 2015
PubMed
15) Tai HC, Chuang IC, Chen TC et al : NAB2-STAT6 fusion types account for clinicopathological variations in solitary fibrous tumors. Mod Pathol 28 : 1324-1335, 2015
PubMed
16) Mehrad M, LaFramboise WA, Lyons MA et al : Wholeexome sequencing identifies unique mutations and copy number losses in calcifying fibrous tumor of the pleura : report of 3 cases and review of the literature. Hum Pathol 78 : 36-43, 2018
PubMed
P.205 掲載の参考文献
1) Errani C, Zhang L, Sung YS et al : A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 50 : 644-653, 2011
PubMed
2) Antonescu CR, Le Loarer F, Mosquera JM et al : Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 52 : 775-784, 2013
PubMed
3) Errani C, Sung YS, Zhang L et al : Monoclonality of multifocal epithelioid hemangioendothelioma of the liver by analysis of WWTR1-CAMTA1 breakpoints. Cancer Genet 205 : 12-17, 2012
PubMed
4) Deyrup AT, Tighiouart M, Montag AG et al : Epithelioid hemangioendothelioma of soft tissue : a proposal for risk stratification based on 49 cases. Am J Surg Pathol 32 : 924-927, 2008
 
5) Weiss SW, Ishak KG, Dail DH et al : Epithelioid hemangioendothelioma and related lesions. Semin Diagn Pathol 3 : 259-287, 1986
PubMed
6) Cohen AJ, Sbaschnig RJ, Hochholzer L et al : Mediastinal hemangiomas. Ann Thorac Surg 43 : 656-659, 1987
PubMed
7) Isaka T, Yokose T, Ito H et al : Case of solitary pulmonary capillary hemangioma : pathological features based on frozen section analysis. Pathol Int 63 : 615-618, 2013
PubMed
8) Boland JM, Colby TV, Folpe AL : Liposarcomas of the mediastinum and thorax : a clinicopathologic and molecular cytogenetic study of 24 cases, emphasizing unusual and diverse histologic features. Am J Surg Pathol 36 : 1395-1403, 2012
PubMed
9) den Bakker MA, Marx A, Mukai K et al : Mesenchymal tumours of the mediastinum--part I. Virchows Arch 467 : 487-500, 2015
PubMed
P.210 掲載の参考文献
1) Lan T, Chen H, Xiong B et al : Primary pleuropulmonary and mediastinal synovial sarcoma : a clinicopathologic and molecular study of 26 genetically confirmed cases in the largest institution of southwest China. Diagn Pathol 11 : 62, 2016
PubMed
2) van de Rijn M, Barr FG, Xiong QB et al : Poorly differentiated synovial sarcoma : an analysis of clinical, pathologic, and molecular genetic features. Am J Surg Pathol 23 : 106-112, 1999
PubMed
3) Hartel PH, Fanburg-Smith JC, Frazier AA et al : Primary pulmonary and mediastinal synovial sarcoma : a clinicopathologic study of 60 cases and comparison with five prior series. Mod Pathol 20 : 760-769, 2007
PubMed
4) Ito J, Asano N, Kawai A et al : The diagnostic utility of reduced immunohistochemical expression of SMARCB1 in synovial sarcomas : a validation study. Hum Pathol 47 : 32-37, 2016
PubMed
5) Baranov E, McBride MJ, Bellizzi AM et al : A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma. Am J Surg Pathol 44 : 922-933, 2020
 
6) Cancer Genome Atlas Research Network. Electronic address : elizabeth.demicco@sinaihealthsystem.ca, Cancer Genome Atlas Research Network. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 171 : 950-965.e28, 2017
 
7) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Soft Tissue and Bone Tumours, 5th ed, IARC, Lyon, 2020
 
8) Hirano H, Maeda H, Takeuchi Y et al : Primary pulmonary Ewing sarcoma. Pathol Int 66 : 239-241, 2016
PubMed
9) Albergo JI, Gaston CL, Laitinen M et al : Ewing's sarcoma : only patients with 100 % of necrosis after chemotherapy should be classified as having a good response. Bone Joint J 98-B : 1138-1144, 2016
PubMed
10) Hung YP, Fletcher CD, Hornick JL : Evaluation of ETV4 and WT1 expression in CIC-rearranged sarcomas and histologic mimics. Mod Pathol 29 : 1324-1334, 2016
PubMed
11) Kao YC, Sung YS, Zhang L et al : BCOR Overexpression Is a Highly Sensitive Marker in Round Cell Sarcomas with BCOR Genetic Abnormalities. Am J Surg Pathol 40 : 1670-1678, 2016
PubMed
P.215 掲載の参考文献
1) Swerdlow SH, Campo E Harris NL et al (eds) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, Lyon, 2017
 
P.220 掲載の参考文献
1) Travis WD, Brambilla E, Muller-Hermelink HK et al (eds) : WHO Classification of Tumours. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus and Heart, 3rd ed, IARC Press, Lyon, 2004
 
2) Hans CP, Weisenburger DD, Greiner TC et al : Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103 : 275-282, 2004
PubMed
3) Swerdlow, SH, Campo E, Harris NL et a (l eds) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, IARC Press, Lyon, 2017
 
4) Maeshima AM, Taniguchi H, Toyoda K et al : Clinicopathologic features of histologic transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma : an analysis of 467 patients. Br J Haematol 174 : 923-931, 2016
PubMed
5) Murase T, Yamaguchi M, Suzuki R et al : Intravascular large B-cell lymphoma (IVLBCL) : a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 109 : 478-485, 2007
 
P.225 掲載の参考文献
1) Pittaluga S, Wilson WH, Jaffe ES : Lymphomatoid granulomatosis. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", Revised 4th ed, IARC Press, Lyon, 2017, pp312-314
 
2) Song JY, Pittaluga S, Dunleavy K et al : Lymphomatoid granulomatosis-asingle institute experience : pathologic findings and clinical correlations. Am J Surg Pathol 39 : 141-156, 2015
 
3) Katzenstein AL, Carrington CB, Liebow AA : Lymphomatoid granulomatosis : insights gained over 4 decades. Am J Surg Pathol 34 : e35-48, 2010
 
4) Wilson WH, Young RM, Schmitz R et al : Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to ingerferon-alpha2b. Blood 87 : 4531-4537, 1996
 
5) Guinee D Jr. Jaffe E, Kingma D et al : Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. Am J Surg Pathol 18 : 753-764, 1994
PubMed
6) McNif f JM, Cooper D, Howe G et al : Lymphomatoid granulomatosis of the skin and lung. An angiocentric T cell-rich B-cell lymphoproliferative disorder. Arch Dermatol 132 : 1464-1470, 1996
 
7) Chan JKC, Guintanilla-Martinez J, Ferry JA : Extranodal NK/T-cell lymphoma, nasal type. in Swerdlow SH, Campo E, Harris NL et al (eds) : "WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues", Revised 4th ed, IARC Press, Lyon, 2017, pp368-371
 
8) Tawatchai P, Sanya S, Thamatohrn A et al : Extranodal NK/T-cell Lymphoma, Nasal Type, Includes Cases of Natural Killer Cell and αβ, γδ, and αβ/γδ T-cell Origin A Comprehensive Clinicopathologic and Phenotypic Study. Am J Surg Pathol 36 : 481-499, 2012
 
9) Hasserjian RP, Harris NL : NK-cell lymphomas and leukemias : a spectrum of tumors with variable manifestations and immunophenotype. Am J Clin Pathol 127 : 860-868, 2007
PubMed
10) Tsang WY, Chan JK, Ng CS et al : Utility of a paraffin section-reactive CD56 antibody (123C3) for characterization and diagnosis of lymphomas. Am J Surg Pathol 20 : 202-210, 1996
PubMed
11) Ohshima K, Suzumiya J, Shimazaki K et al : Nasal T/NK cell lymphomas commonly express perforin and Fas ligand : important mediators of tissue damage. Histopathology 31 : 444-450, 1997
PubMed
P.229 掲載の参考文献
1) Mourah S, How-Kit A, Meignin V et al : Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis. Eur Respir J 47 : 1785-1796, 2016
PubMed
2) Jouenne F, Chevret S, Bugnet E et al : Genetic landscape of adult Langerhans cell histiocytosis with lung involvement. Eur Respir J 55 : 1901190, 2020
PubMed
3) Roden AC, Hu X, Kip S et al : BRAF V600E expression in Langerhans cell histiocytosis : clinical and immunohistochemical study on 25 pulmonary and 54 extrapulmonary cases. Am J Surg Pathol 38 : 548-551, 2014
 
4) Brown NA, Elenitoba-Johnson KSJ : Clinical implications of oncogenic mutations in pulmonary Langerhans cell histiocytosis. Curr Opin Pulm Med 24 : 281-286, 2018
PubMed
5) Diamond EL, Dagna L, Hyman DM et al : Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood 124 : 483-492, 2014
PubMed
6) Papo M, Diamond EL, Cohen-Aubart F et al : High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood 130 : 1007-1013, 2017
PubMed
7) Ozkaya N, Rosenblum MK, Durham BH et al : The histopathology of Erdheim-Chester disease : a comprehensive review of a molecularly characterized cohort. Modern Pathol 31 : 581-597, 2018
 
8) Hervier B, Haroche J, Arnaud L et al : Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood 124 : 1119-1126, 2014
 
9) Arnaud L, Gorochov G, Charlotte F et al : Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease : a single-center series of 37 patients, Blood 117 : 2783-2790, 2011
PubMed
10) Durham BH, Roos-Weil D, Baillou C et al : Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood 130 : 176-180, 2017
PubMed
11) Ghobadi A, Miller CA, Li T et al : Shared cell of origin in a patient with Erdheim-Chester disease and acute myeloid leukemia. Haematologica 104 : e373-e375, 2019
 
P.236 掲載の参考文献
1) Miller J, Shoni M, Siegert C et al : Benign Metastasizing Leiomyomas to the Lungs : An Institutional Case Series and a Review of the Recent Literature. Ann Thorac Surg 101 : 253-258, 2016
 
2) Larsen BT, Klein JR, Hornychova H et al : Diffuse intrapulmonary malignant mesothelioma masquerading as interstitial lung disease : a distinctive variant of mesothelioma. The American journal of surgical pathology 37 : 1555-1564, 2013
PubMed
3) Nind NR, Attanoos RL, Gibbs AR : Unusual intraparenchymal growth patterns of malignant pleural mesothelioma. Histopathology 42 : 150-155, 2003
PubMed
4) Detterbeck FC, Nicholson AG, Franklin WA et al : The IASLC Lung Cancer Staging Project : Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol 11 : 639-650, 2016
PubMed
5) Detterbeck FC, Franklin WA, Nicholson AG et al : The IASLC Lung Cancer Staging Project : Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer. J Thorac Oncol 11 : 651-665, 2016
PubMed
6) Chang JC, Alex D, Bott M et al : Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases : Comparison with Standard Histopathologic Approach. Clin Cancer Res 25 : 7113-7125, 2019
PubMed
7) Takemura C, Kashima J, Hashimoto T et al : A mimic of lung adenocarcinoma : a case report of histological conversion of metastatic thyroid papillary carcinoma. Histopathology 80 : 1004-1007, 2022
PubMed
8) Yatabe Y, Dacic S, Borczuk AC et al : Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol 14 : 377-407, 2019
PubMed
9) Yatabe Y, Borczuk AC, Cooper WA et a (l eds) : IASLC Atlas of DIagnostic Immunohistochemistry. IASLC Publication, Denver, 2020
 
10) Gruchy JR, Barnes PJ, Dakin Hache KA : CytoLytR fixation and decalcification pretreatments alter antigenicity in normal tissues compared with standard formalin fixation. Appl Immunohistochem Mol Morphol 23 : 297-302, 2015
 
11) Ordonez NG : Value of PAX 8 immunostaining in tumor diagnosis : a review and update. Adv Anat Pathol 19 : 140-151, 2012
 
12) Miettinen M, McCue PA, Sarlomo-Rikala M et al : GATA3 : a multispecific but potentially useful marker in surgical pathology : a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol 38 : 13-22, 2014
PubMed
13) Terra S, Roden AC, Aubry MC et al : Utility of Immunohistochemistry for MUC4 and GATA3 to Aid in the Distinction of Pleural Sarcomatoid Mesothelioma From Pulmonary Sarcomatoid Carcinoma. Arch Pathol Lab Med 145 : 208-213, 2021
PubMed
14) Prabhakaran S, Hocking A, Kim C et al : The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas. Hum Pathol 105 : 1-8, 2020
PubMed
15) Klaric KA, Riaz N, Asleh K et al : SRY-box transcription factor 10 is a highly specific biomarker of basal-like breast cancer. Histopathology 80 : 589-597, 2022
PubMed
16) Ai D, Yao J, Yang F et al : TRPS1 : a highly sensitive and specific marker for breast carcinoma, especially for triplenegative breast cancer. Mod Pathol 34 : 710-719, 2021
PubMed
17) Matsuda K, Kashima J, Yatabe Y : The Isoform Matters in NUT Carcinoma : A Diagnostic Pitfall of p40 Immunohistochemistry. J Thorac Oncol 15 : e176-e178, 2020
PubMed
P.239 掲載の参考文献
1) Barnas E, Ksiazek M, Ras R et al : Benign metastasizing leiomyoma : A review of current literature in respect to the time and type of previous gynecological surgery. PLoS One 12 : e0175875, 2017
 
2) Perri T, Komem DA, Apter S et al : Spontaneous versus morcellator-related benign metastasizing leiomyoma-A retrospective study. Int J Gynaecol Obstet 157 : 110-114, 2021
PubMed
3) Enomoto T, Aoki M, Kouzaki Y et al : WHO Grade I Meningioma Metastasis to the Lung 26 Years after Initial Surgery : A Case Report and Literature Review. NMC Case Rep J 6 : 125-129, 2019
 
4) Doyle LA, Fletcher CDM : Metastasizing 'benign' cutaneous fibrous histiocytoma : a clinicopathologic analysis of 16 cases. Am J Surg Pathol 37 : 484-495, 2013
PubMed
5) Nucci MR, Drapkin R, Dal Cin P et al : Distinctive cytogenetic profile in benign metastasizing leiomyoma : pathogenetic implications. Am J Surg Pathol 31 : 737-743, 2007
PubMed
6) Pandiar D, Anand R, Kamboj M et al : Metastasizing Ameloblastoma : A 10 Year Clinicopathological Review with an Insight Into Pathogenesis. Head Neck Pathol 15 : 967-974, 2021
PubMed
7) Knight J, Ratnasingham K : Metastasising pleomorphic adenoma : Systematic review. Int J Surg 19 : 137-145, 2015
 
8) Lewis EI, Chason RJ, DeCherney AH et al : Novel hormone treatment of benign metastasizing leiomyoma : an analysis of five cases and literature review. Fertil Steril 99 : 2017-2024, 2013
PubMed
9) 加藤文章, 巻幡聰, 佐藤勇一郎 他 : 17年前の子宮平滑筋腫瘍所見から転移性肺平滑筋肉腫と診断した1例. 日呼外会誌 35 : 332-336, 2021
 
10) 前田純, 東山聖彦, 西尾渉 他 : いわゆる肺良性転移性平滑筋腫10例の臨床病理学的検討. 日呼外会誌 35 : 537-546, 2021
 
11) Wu R-C, Chao A-S, Lee L-Y et al : Massively parallel sequencing and genome-wide copy number analysis revealed a clonal relationship in benign metastasizing leiomyoma. Oncotarget 8 : 47547-47554, 2017
PubMed
P.244 掲載の参考文献
1) Koo CW, Baliff JP, Torigian DA et al : Spectrum of pulmonary neuroendocrine cell proliferation : diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, tumorlet, and carcinoids. AJR Am J Roentgenol 195 : 661-668, 2010
PubMed
2) Dermawan JK, Mukhopadhyay S : Insulinoma-associated protein 1 (INSM1) differentiates carcinoid tumourlets of the lung from pulmonary meningothelial-like nodules. Histopathology 72 : 1067-1069, 2017
 
3) Finkelstein SD, Hasegawa T, Colby T et al : 11q13 allelic imbalance discriminates pulmonary carcinoids from tumorlets. A microdissection-based genotyping approach useful in clinical practice. Am J Pathol 155 : 633-640, 1999
PubMed
4) Mukhopadhyay S, El-Zammar OA, Katzenstein AL : Pulmonary meningothelial-like nodules : new insights into a common but poorly understood entity. Am J Surg Pathol 33 : 487-495, 2009
PubMed
5) Mizutani E, Tsuta K, Maeshima AM et al : Minute pulmonary meningothelial-like nodules : clinicopathologic analysis of 121 patients. Hum Pathol 40 : 678-682, 2009
PubMed
6) Niho S, Yokose T, Nishiwaki Y et al : Immunohistochemical and clonal analysis of minute pulmonary meningothelial-like nodules. Hum Pathol 30 : 425-429, 1999
PubMed
7) Weissferdt A, Tang X, Suster S et al : Pleuropulmonary Meningothelial Proliferations : Evidence for a Common Histogenesis. Am J Surg Pathol39 : 1673-1678, 2015
 
8) Maruyama H, Ohbayashi C, Hino O et al : Pathogenesis of multifocal micronodular pneumocyte hyperplasia and lymphangioleiomyomatosis in tuberous sclerosis and association with tuberous sclerosis genes TSC1 and TSC2. Pathol Int 51 : 585-594, 2001
PubMed
9) Kobashi Y, Sugiu T, Mouri K et al : Clinicopathological analysis of multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis in Japan. Respirology 13 : 1076-1081, 2008
PubMed
10) Hayashi T, Kumasaka T, Mitani K et al : Loss of heterozygosity on tuberous sclerosis complex genes in multifocal micronodular pneumocyte hyperplasia. Mod Pathol 23 : 1251-1260, 2010
PubMed
11) Inoue C, Saito R, Kishikawa S et al : Novel genetic characteristics of multifocal micronodular pneumocyte hyperplasia (MMPH) : a case report with frequent BRAF mutations analyzed by next-generation sequencing supporting benign behaviors of MMPH. Virchows Archiv 479 : 637-641, 2021
PubMed
P.249 掲載の参考文献
1) Hamano H, Kawa S, Horiuchi A et al : High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 8 : 732-738, 2001
 
2) Umehara H, Okazaki K, Masaki Y et al : Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol 22 : 21-30, 2012
PubMed
3) 梅原久範, 岡崎和一, 川茂幸, 他 : 2020年改訂 IgG4関連疾患包括診断基準The 2020 Revised Comprehensive Diagnostic (RCD) Criteria for IgG4-RD. 日内会誌 110 : 962-969, 2021
 
4) Deshpande V, Zen Y, Chan JK et al : Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25 : 1181-1192, 2012
PubMed
5) 松井祥子, 山本洋, 源誠二郎, 他 : 第54回日本呼吸器学会学術講演会 シンポジウム報告 IgG4関連呼吸器疾患の診断基準. 日呼吸誌 4 : 129-132, 2015
 
6) 山本洋 : IgG4関連呼吸器疾患. 信州医誌 65 : 81-91, 2017
Medical*Online
7) Kinugawa Y, Uehara T, Iwaya M et al : IL-6 expression helps distinguish Castleman's disease from IgG4-related disease in the lung. BMC Pulm Med 21 : 219, 2021
PubMed
8) Sato Y, Kojima M, Takata K et al : Multicentric Castleman's disease with abundant IgG4-positive cells : a clinical and pathological analysis of six cases. J Clin Pathol 63 : 1084-1089, 2010
 
9) Fujimoto M, Yoshizawa A, Sumiyoshi S et al : Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer. Hum Pathol 44 : 1569-1576, 2013
PubMed
P.255 掲載の参考文献
1) 堤寛 : 結核症. 感染症病理アトラス, 文光堂, 2000
 
2) 蛯澤晶, 木谷匡志, 清水宏繁 他 : 結核性と非結核性抗酸菌症. 病理と臨床 36 (臨増) : 170-178, 2018
 
3) 清水重喜 : 感染性肉芽腫性疾患. 病理と臨床 32 : 1134-1140, 2014
Medical*Online
4) Travis WD, Colby TV, Koss MN et al : Non-Neoplastic Disorders of the Lower Respiratory Tract. Atlas of Nontumor Pathology, American Registry of Pathology, Washington, DC, 2002, pp600-626
 
5) 堤寛 : アスペルギルス症, ムコール症. 感染症病理アトラス, 文光堂, 2000
 
6) 堤寛 : フィラリア症, オンコセルカ症, 犬糸状虫症. 感染症病理アトラス, 文光堂, 2000
 
7) Milanez de Campos JR, Barbas CS, Filomeno LT et al : Human pulmonary dirofilariasis : analysis of 24 cases from Sao Paulo, Brazil. Chest 112 : 729-733, 1997
 
P.262 掲載の参考文献
1) Channabasavaiah AD, Joseph JV : Thoracic endometriosis : revisiting the association between clinical presentation and thoracic pathology based on thoracoscopic findings in 110 patients. Medicine 89 : 183-188, 2010
PubMed
2) Fujimoto K, Kasai H, Suga M et al : Pulmonary Endometriosis which Probably Occurred through Hematogenous Metastasis after Artificial Abortion. Intern Med 56 : 1405-1408, 2017
PubMed
3) Corbett HJ, Humphrey GME : Pulmonary sequestration. Paediatr Respir Rev 5 : 59-68, 2004
PubMed
4) Travis WD : Non-Neoplastic Disorders of the Lower Respiratory Tract. Atlas of Nontumor Pathology, ARP Press, Silver Spring, 2002
 
5) Desai S, Dusmet M, Ladas G et al : Secondary vascular changes in pulmonary sequestrations. Histopathology 57 : 121-127, 2010
PubMed
6) 巽浩一郎 : 肺動静脈瘻. 呼吸 27 : 169-172, 2008
Medical*Online
7) Lhote R, Haroche J, Duron L et al : Pulmonary hyalinizing granuloma : a multicenter study of 5 new cases and review of the 135 cases of the literature. Immunol Res 65 : 375-385, 2017
PubMed
8) Ishige I, Usui Y, Takemura T et al : Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. Lancet 354 : 120-123, 1999
PubMed
P.266 掲載の参考文献
1) Carney JA, Sheps SG, Go VL et al : The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med 296 : 1517-1518, 1977
PubMed
2) Carney JA : Carney triad. Front Horm Res 41 : 92-110, 2013
PubMed
3) Carney JA : Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad) : natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 74 : 543-552, 1999
PubMed
4) 坪井光弘, 吉澤潔, 環正文 他 : 不完全型Carney's triadの1例-本邦報告11例の臨床的検討-. 日呼外会誌 26 : 79-84, 2012
 
5) 常塚啓彰, 加藤大志朗, 下村雅律 他 : 初回切除後19年目に肺・胃の再切除を行った不完全型Carney's triadの1例. 日呼外会誌 28 : 748-753, 2014
 
6) Rodriguez FJ, Aubry MC, Tazelaar HD et al : Pulmonary chondroma : a tumor associated with Carney triad and different from pulmonary hamartoma. Am J Surg Pathol 31 : 1844-1853, 2007
PubMed
7) Settas N, Faucz FR, Stratakis CA : Succinate dehydrogenase (SDH) deficiency, Carney triad and the epigenome. Mol Cell Endocrinol 469 : 107-111, 2018
PubMed
8) Gridelli C, Rossi A, Carbone DP et al : Non-small-cell lung cancer. Nat Rev Dis Primers 1 : 15009, 2015
PubMed
9) Pao W, Girard N : New driver mutations in non-small-cell lung cancer. Lancet Oncol 12 : 175-180, 2011
PubMed
10) Yamamoto H, Yatabe Y, Toyooka S : Inherited lung cancer syndromes targeting never smokers. Transl Lung Cancer Res 7 : 498-504, 2018
PubMed
11) Bell DW, Gore I, Okimoto RA et al : Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37 : 1315-1316, 2005
PubMed
12) Ikeda K, Nomori H, Mori T et al : Novel germline mutation : EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg 85 : 1430-1432, 2008
PubMed
13) Prudkin L, Tang X, Wistuba II : Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. J Thorac Oncol 4 : 139-141, 2009
PubMed
14) Girard N, Lou E, Azzoli CG et al : Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol : a preliminary report. Clin Cancer Res 16 : 755-763, 2010
PubMed
15) Ohtsuka K, Ohnishi H, Kurai D et al : Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation. J Clin Oncol 29 : e191-e192, 2011
PubMed
16) Tibaldi C, Giovannetti E, Vasile E et al : Inherited germline T790M mutation and somatic epidermal growth factor receptor mutations in non-small cell lung cancer patients. J Thorac Oncol 6 : 395-396, 2011
PubMed
17) Oxnard GR, Miller VA, Robson ME et al : Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol 7 : 1049-1052, 2012
PubMed
18) Demierre N, Zoete V, Michielin O et al : A dramatic lung cancer course in a patient with a rare EGFR germline mutation exon 21 V843I : Is EGFR TKI resistance predictable? Lung Cancer 80 : 81-84, 2013
 
19) van Noesel J, van der Ven WH, van Os TA et al : Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation. J Clin Oncol 31 : e161-e164, 2013
PubMed
20) Gazdar A, Robinson L, Oliver D et al : Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations. J Thorac Oncol 9 : 456-463, 2014
PubMed
21) Lu S, Yu Y, Li Z et al : EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer. J Thorac Oncol 14 : 732-736, 2019
 
22) Yamamoto H, Higasa K, Sakaguchi M et al : Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst 106 : djt338, 2014
PubMed
23) Suzawa K, Toyooka S, Sakaguchi M et al : Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations. Cancer Sci 107 : 45-52, 2016
PubMed
24) Yamamoto H, Toyooka S, Ninomiya T et al : Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E. Oncologist 23 : 150-154, 2018
PubMed
P.272 掲載の参考文献
1) Travis W, Brambilla E, Burke AP et al (eds) : WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th ed, IARC Press, Lyon, 2015
 
2) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Thoracic tumours, 5th ed, IARC, Lyon, 2021
 
3) Thunnissen E, Beasley MB, Borczuk AC et al : Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 25 : 1574-1583, 2012
PubMed
4) Shih AR, Uruga H, Bozkurtlar E et al : Problems in the reproducibility of classification of small lung adenocarcinoma : an international interobserver study. Histopathology 75 : 649-659, 2019
PubMed
5) 日本肺癌学会 (編) : 切り出しマニュアル. 肺癌取扱い規約, 第8版補訂版, 金原出版, 2021
 
6) Thunnissen E, Belien JAM, Kerr KM et al : In Compressed Lung Tissue Microscopic Sections of Adenocarcinoma In Situ May Mimic Papillary Adenocarcinoma. Arch Pathol Lab Med 137 : 1792-1797, 2013
PubMed
7) Moreira AL, Ocampo PS, Xia Y et al : A Grading System for Invasive Pulmonary Adenocarcinoma : A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol 15 (10) : 1599-1610, 2020
 
8) Honda T, Ota H, Sano K, Yoshizawa A : Alveolar shrinkage in bronchioloalveolar carcinoma without central fibrosis. Lung Cancer 36 : 283-288, 2002
PubMed
9) Noguchi M, Morikawa A, Kawasaki M et al : Small Adenocarcinoma of the Lung Histologic Characteristics and Prognosis. Cancer 75 : 2844-2852, 1995
PubMed
10) Yotsukura M, Asamura H, Suzuki S et al : Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma. Lung Cancer 145 : 158-166, 2020
 
11) Mecham RP : Elastin in lung development and disease pathogenesis. Matrix Biol 73 : 6-20, 2018
PubMed
12) Eto T, Suzuki H, Honda A et al : The changes of the stromal elastotic framework in the growth of peripheral lung adenocarcinomas. Cancer 77 : 646-656, 1996
PubMed
13) Thunissen E, Motoi N, Minami Y et al : Elastin in pulmonary pathology : relevance in tumors with lepidic and/or papillar y appearance. A comprehensive understanding from a morphological viewpoint. Histopathology 80 : 457-467, 2021
 
14) Kadota K, Nitadori J, Sima CS et al : Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences following limited resection for small stage I lung adenocarcinomas. J Thrac Oncol 10 : 806-814, 2015
 
15) Radonic T, Dickhoff C, Mino-Kenudson M et al : Gross handling of pulmonary resection specimen : maintaining the 3-dimensional orientation. J Thorac Dis 11 : S37-S44, 2019
PubMed
16) Fukutomi T, Hayashi Y, Emoto K et al : Low papillary structure in lepidic growth component of lung adenocarcinoma : a unique histologic hallmark of aggressive behavior. Human Pathol 44 : 1849-1858, 2013
PubMed
17) Nakazato Y, Minami Y, Kobayashi H et al : Nuclear grading of pulmonary adenocarcinoma. Correlation between nuclear size and prognosis. Cancer 116 : 2011-2019, 2010
PubMed
18) Thunnissen E, Borczuk AC, Flieder DB et al : The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases. J Thorac Oncol 12 : 334-346, 2017
 
P.279 掲載の参考文献
1) 武田麻衣子, 大林千穂 : 肺腫瘍の迅速診断. 病理と臨床 39 : 35-40, 2021
Medical*Online
2) Walts AE, Marchevsky AM : Root cause analysis of problems in the frozen section diagnosis of in situ, minimally invasive, and invasive adenocarcinoma of the lung. Arch Pathol Lab Med 136 : 1515-1521, 2012
PubMed
3) He P, Yao G, Guan Y et al : Diagnosis of lung adenocarcinoma in situ and minimally invasive adenocarcinoma from intraoperative frozen sections : an analysis of 136 cases. J Clin Pathol 69 : 1076-1080, 2016
 
4) Liu S, Wang R, Zhang Y et al : Precise Diagnosis of Intraopb erative Frozen Section Is an Effective Method to Guide Resection Strategy for Peripheral Small-Sized Lung Adenocarcinoma. J Clin Oncol 34 : 307-313, 2016
 
5) Tang J, Cui Y, Li B et al : Mathematical prediction model of computed tomography signs is superior to intraoperative frozen section in the diagnosis of ground-glass nodular invasive adenocarcinoma of the lung. Thorac Cancer 12 : 2382-2387, 2021
PubMed
6) Kadota K, Kushida Y, Kagawa S et al : Limited resection is associated with a higher risk of locoregional recurrence than lobectomy in stage I lung adenocarcinoma with tumor spread through air spaces. Am J Surg Pathol 43 : 1033-1041, 2019
 
7) Eguchi T, Kameda K, Lu S et al : Lobectomy is associated with better outcomes than sublobar resection in spread through air spaces (STAS) -positive T1 lung adenocarcinoma : a propensity score-matched analysis. J Thorac Oncol 14 : 87-98, 2019
PubMed
8) Zhou F, Villalba JA, Sayo TMS et al : Assessment of the feasibility of frozen sections for the detection of spread through air spaces (STAS) in pulmonary adenocarcinoma. Mod Pathol 35 : 210-217, 2022
PubMed
9) Moreira AL, Ocampo PS, Xia Y et al : A Grading system for invasive pulmonary adenocarcinoma : a proposal from the IASLC pathology committee. J Thorac Oncol 15 : 1599-1610, 2020
 
10) Shang Z, Han Y, Shao J et al : Challenging of frozen diagnoses of small sclerosing pneumocytoma. J Clin Pathol 74 : 730-734, 2021
PubMed
11) Yang CH, Lee LY : Pulmonary sclerosing pneumocytoma remains a diagnostic challenge using frozen sections : a clinicopathological analysis of 59 cases. Histopathology 72 : 500-508, 2018
PubMed
12) Yang Y, Xie X, Jiang G et al : Clinicopathological characteristic of ciliated muconodular papillary tumour of the lung. J Clin Pathol 75 : 128-132, 2022
PubMed
13) Sugiyama T, Tajiri T, Fujita H et al : The approach of scratch-imprint cytology : Is it an alternative to frozen section for intraoperative assessment of pulmonary lesions? Pathol Int 70 : 31-39, 2020
PubMed
14) Owen RM, Force SD, Gal AA et al : Routine intraoperative frozen section analysis of bronchial margins is of limited utility in lung cancer resection. Ann Thorac Surg 95 : 1859-1865, 2013
PubMed
15) Gagne A, Racine E, Orain M et al : Identification of Grossing Criteria for Intraoperative Evaluation by Frozen Section of Lung Cancer Resection Margins. Am J Surg Pathol 42 : 1495-1502, 2018
PubMed
P.285 掲載の参考文献
1) Ordonez NG : Thyroid transcription factor-1 is a marker of lung and thyroid carcinomas. Adv Anat Pathol 7 : 123-127, 2000
PubMed
2) Yatabe Y, Mitsudomi T, Takahashi T : TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 26 : 767-773, 2002
PubMed
3) Yatabe Y, Dacic S, Borczuk AC et al : Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. J Thorac Oncol 14 : 377-407, 2019
PubMed
4) Matoso A, Singh K, Jacob R et al : Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol 18 : 142-149, 2010
PubMed
5) Micke P, Mattsson JSM, Djureinovic D et al : The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs. J Thorac Oncol 11 : 862-872, 2016
PubMed
6) Fatima N, Cohen C, Lawson D et al : TTF-1 and Napsin A double stain : a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks. Cancer Cytopathol 119 : 127-133, 2011
 
7) 稲村健太郎, 二宮浩範, 石川雄一 : 肺癌の病理診断と免疫組織化学-Advanced Staining News-Vol 7. Leica Biosystems. Published November 2016
 
8) 石井源一郎 : 肺癌の病理組織分類-Update-. 肺癌 58 (Suppl) : 898-902, 2018
 
9) Ordonez NG : Value of thyroid transcription factor-1 immunostaining in tumor diagnosis : a review and update. Appl Immunohistochem Mol Morphol 20 : 429-444, 2012
PubMed
10) Pelosi G, Fabbri A, Tamborini E et al : Challenging Lung Carcinoma with Coexistent ΔNp63/p40 and Thyroid Transcription Factor-1 Labeling Within the Same Individual Tumor Cells. J Thorac Oncol 10 : 1500-1502, 2015
 
11) Bishop JA, Teruya-Feldstein J, Westra WH et al : p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 25 : 405-415, 2012
 
12) Micke P, Botling J, Mattsson JSM et al : Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer. Sci Rep 9 : 1319, 2019
PubMed
P.292 掲載の参考文献
1) Sholl LM, Kadota K, Sauter JL : Metastasis to the pleura. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp459-462
 
2) Tanaka H, Akiyama Y, Kitamura A et al : Malignant mesothelioma with squamous differentiation. Histopathology 72 : 1216-1220, 2018
PubMed
3) Mogi A, Nabeshima K, Hamasaki M et al : Pleural malignant mesothelioma with invasive micropapillary component and its association with pulmonary metastasis. Pathol Int 59 : 874-879, 2009
PubMed
4) Husain AN, Colby TV, Ordonez NG et al : Guidelines for pathologic diagnosis of malignant mesothelioma. 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arcch Pathol Lab Med 142 : 89-108, 2018
 
5) Sauter JL, Bueno R, Dacic S et al : Diffuse pleural mesothelioma. in WHO Classification of Tumours Editorial Board (ed) : "WHO Classification of Tumours : Thoracic Tumours", 5th ed, IARC, Lyon, 2021, pp204-219
 
6) 廣島健三, 呉迪 他 : 中皮腫以外の腫瘍におけるHEG1の発現. 廣島健三 (編) : 平成30年度石綿関連疾患に係る医学的所見の解析調査業務 (新たな免疫染色抗体を用いた中皮腫診断法の開発に関する調査編) 報告書, 東京女子医科大学, 2019, pp21-30
 
7) Soini Y, Kinnula V, Kahlos K et al : Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. J Clin Pathol 59 : 250-254, 2006
PubMed
8) Ordonez NG : Value of claudin-4 immunostaining in the diagnosis of mesothelioma. Am J Clin Pathol 139 : 611-619, 2013
PubMed
9) Mawas AS, Amatya VJ, Kushitani K et al : MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung. Sci Rep 8 : 134, 2018
PubMed
10) Granville LA, Younes M, Andrew Churg A et al : Comparison of monoclonal versus polyclonal calretinin antibodies for immunohistochemical diagnosis of malignant mesothelioma. Appl Immunohistochem Mol Morphol 13 : 75-79, 2005
PubMed
11) Chapel DB, Schulte JJ, Husain AN et al : Application of immunohistochemistry in diagnosis and management of malignant mesothelioma. Transl Lung Cancer Res 9 (Suppl 1) : S3-S27, 2020
 
12) 酒井康裕, 大林千穂 : 中皮腫と肺癌の胸膜浸潤との鑑別. 深山正久, 松野吉宏, 野口雅之 (編) : 縦隔腫瘍・胸膜腫瘍 腫瘍病理鑑別診断アトラス, 文光堂, 2014, pp255-261
 
13) Marchevsky AM, LeStang N, Hiroshima K et al : The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung : evidence-based guidelines from the international Mesothelioma Panel and the MESOPATH National Reference Center. Hum Pathol 67 : 160-168, 2017
PubMed
14) Berg KB, Churg A : GATA3 immunohistochemistry for distinguishing sarcomatoid mesothelioma from sarcomatoid carcinoma of the lung. Am J Surg Pathol 41 : 1221-1225, 2017
PubMed
15) Amatya VJ, Kushitani K, Mawas AS et al : MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural mesothelioma from lung sarcomatoid carcinoma. Mod Pathol 30 : 672-681, 2017
PubMed
16) Liu X, Jia Y, Stoopler MB et al : Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. J Clin Oncol 34 : 794-802, 2016
 
17) Nind NR, Attanoos RL, Gibbs AR : Unusual intraparenchymal growth patterns of malignant pleural mesothelioma. Histopathology 42 : 150-155, 2003
PubMed
18) Hida T, Hamasaki M, Matsumoto S et al : Diffuse intrapulmonary malignant mesothelioma presenting with miliary pulmonary nodules : A case report. Pathol Int 65 : 318-323, 2015
PubMed
19) Jimbo N, Kawahara K, Tsukamoto R et al : Malignant pleural mesothelioma showing intrapulmonary lepidic spread. Pathol Int 70 : 373-375, 2020
PubMed
P.298 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Thoracic Tumours, 5th ed, IARC, Lyon, 2021
 
2) 谷田部恭 : 生検組織の扱い. 病理と臨床 34 : 244-248, 2016
Medical*Online
3) Matoso A, Singh K, Jacob R et al : Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol 18 : 142-149, 2010
PubMed
4) Tran L, Mattsson JSM, Nodin B et al : Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung Carcinoma. Appl Immunohistochem Mol Morphol 24 : 648-659, 2016
PubMed
5) Micke P, Mattsson JSM, Djureinovic D et al : The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs. J Thorac Oncol 11 : 862-872, 2016
PubMed
P.307 掲載の参考文献
1) 村田喜代史, 上甲剛, 村山貞之 他 (編) : 胸部のCT, 第4版, メディカルサイエンスインターナショナル, 2018
 
2) Okami J, Shintani Y, Okumura M et al : Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010. J Thorac Oncol 14 : 212-222, 2019
PubMed
3) 日本肺癌学会 (編) : 臨床・病理 肺癌取扱い規約, 第8版補訂版, 金原出版, 2021
 
4) 日本肺癌学会 (編) : 肺癌診療ガイドライン 2020年版, 金原出版, 2021
 
5) Mendoza DP, Piotrowska Z, Lennerz JK et al : Role of imaging biomarkers in mutation-driven non-small cell lung cancer. World J Clin Oncol 11 : 412-427, 2020
PubMed
6) Ninomiya H, Hiramatsu M, Inamura K et al : Correlation between morphology and EGFR mutations in lung adenocarcinomas significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 63 : 235-340, 2009
PubMed
7) Kim TH, Woo S, Yoon SH et al : CT characteristics of non-small cell lung cancer with anaplastic lymphoma kinase rearrangement : A systematic review and meta-analysis. AJR Am J Roentgenol 213 : 1059-1072, 2019
PubMed
8) Kim H, Chung JH : Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement. Transl Lung Cancer Res 4 : 149-155, 2015
 
9) Lee B, Lee T, Lee SH et al : Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers. Oncotarget 17 : 23874-23884, 2016
 
10) Toyokawa G, Takada K, Okamoto T et al : Computed tomography features of lung adenocarcinomas with programmed death ligand 1 expression. Clin Lung Cancer 18 : e375-e383, 2017
PubMed
11) Wu T, Zhou F, Soodeen-Lalloo AK et al : The association between imaging features of TSCT and the expression of PD-L1 in patients with surgical resection of lung adenocarcinoma. Clin Lung Cancer 20 : e195-e207, 2019
PubMed
12) Yanagawa M, Johkoh T, Noguchi M et al : Radiological prediction of tumor invasiveness of lung adenocarcinoma on thin-section CT. Medicine 96 : e6331, 2017
PubMed
13) Yanagawa M, Kusumoto M, Johkoh T et al : Radiologicpathologic correlation of solid portions on thin-section CT images in lung adenocarcinoma : a multicenter study. Clin Lung Cancer 19 : e303-e312, 2018
 
14) Yanagawa M, Tsubamoto M, Sato Y et al : Lung adenocarcinoma at CT with 0.25-mm section thickness and a 2048 matrix : High-spatial- resolution imaging for predicting invasiveness. Radiology 297 : 462-471, 2020
 
15) Johnston RP, Emoto K, Dux J et al : Predicting spread through air spaces (STAS) preoperatively : can imaging help? J Thorac Dis 11 : S1938-S1941, 2019
PubMed
16) Crow J, Slavin G, Kreel L : Pulmonary metastasis : a pathologic and radiologic study. Cancer 47 : 2595-2602, 1981
PubMed
17) 日本呼吸器内視鏡学会 (編) : 気管支鏡テキスト, 第3版, 医学書院, 2019, pp119-141
 
18) Kandathil A, Kay FU, Butt YM et al : Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer. Radio Graphics 38 : 2134-2149, 2018
 
19) Suarez-Pinera M, Belda-Sanchis J, Taus A et al : FDG PET-CT SUVmax and IASLC/ATS/ERS histologic classification : a new profile of lung adenocarcinoma with prognostic value. J Nucl Med Mol Imaging 8 : 100-109, 2018
 
20) Nishii K, Bessho A, Fukamatsu N et al : Statistical analysis of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography ground-glass nodule findings. Mol Clin Oncol 9 : 279-282, 2018
 
21) Niu R, Shao X, Shao X et al : Lung Adenocarcinoma Manifesting as Ground-Glass Opacity Nodules 3 cm or Smaller : Evaluation With Combined High-Resolution CT and PET/CT Modality. AJR Am J Roentgenol 213 : W236-W245, 2019
PubMed
22) Jiang Y, Hou G, Cheng W : The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid : A systematic review and meta-analysis. Medicine 98 : e14769, 2019
PubMed
23) Jiang L, Huang Y, Tang Q et al : 18F-FDG PET/CT characteristics of pulmonary sclerosing hemangioma vs. pulmonary hamartoma. Oncol Lett 16 : 660-665, 2018
 
24) Travis WD, Asamura H, Bankier AA et al : The IASLC Lung Cancer Staging Project : Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol 11 : 1204-1223, 2016
PubMed
P.314 掲載の参考文献
1) 日本肺癌学会 (編) : 臨床・病理 肺癌取扱い規約, 第8版補訂版, 金原出版, 2021
 
2) 村岡昌司, 赤嶺晋治, 土谷智史 他 : 術前未確定診断の肺腫瘤性病変に対する術中吸引針生検の有用性と安全性に関する検討. 日呼外会誌 20 : 700-705, 2006
 
3) Satoh Y, Hoshi R, Ishikawa Y et al : Recurrence patterns in patients with early stage non-small cell lung cancers undergoing positive pleural lavage cytology. Ann Thorac Surg 83 : 197-202, 2007
PubMed
4) Saso S, Rao C, Ashrafian H et al : Positive pre-resection pleural lavage cytology is associated with increased risk of lung cancer recurrence in patients undergoing surgical resection : a meta-analysis of 4450 patients Thorax 67 : 526-532, 2012
PubMed
5) 園田大, 佐藤之俊 : 呼吸器細胞診update-診断およびバイオマーカーへの活用と課題-. 肺癌 60 : 373-378, 2020
Medical*Online
6) Feller-Kopman D, Yung RC, Burroughs F et al : Cytology of endobronchial ultrasound-guided transbronchial needle aspiration : a retrospective study with histology correlation. Cancer 117 : 482-490, 2009
PubMed
7) 日本臨床細胞学会. http://jscc.or.jp/wp-content/themes/jscc/guidelines/がんゲノム診療における細胞検体の取扱い指針_20210604.pdf
 
8) Hiroshima K, Yoshizawa A, Takenaka A et al : Cytology reporting system for lung cancer from Japan Lung Cancer Society and Japanese Society of Clinical Cytology : An interobserver reproducibility study and risk of malignancy evaluation on cytology specimens. Acta Cytol 64 : 452-462, 2020
PubMed
9) Kakinuma H, Mikami T, Iwabuchi K et al : Diagnostic findings of bronchial brush cytology for pulmonary large cell neuroendocrine carcinomas. Comparison with poorly differentiated adenocarcinomas, squamous cell carcinomas, and small cell carcinomas. Cancer Cytopathol 99 : 247-254, 2003
 
10) Hiroshima K, Abe S, Ebihara Y et al : Cytological characteristics of pulmonary large cell neuroendocrine carcinoma. Lung Cancer 48 : 331-337, 2005
PubMed
11) Hoshi R, Tsuzuku M, Horai T et al : Discriminant model for cytologic distinction of large cell neuroendocrine carcinoma from small cell carcinoma of the lung. J Thorac Oncol 5 : 472-478, 2010
 
12) Satoh Y, Hoshi R, Horai T et al : Association of cytologic micropapillary clusters in cytology samples with lymphatic spread in clinical stage I lung adenocarcinomas. Lung Cancer 64 : 277-281, 2009
 
P.320 掲載の参考文献
1) Shimizu H, Okada M, Toh Y et al : Thoracic and cardiovascular surgeries in Japan during 2018 : Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 69 : 179-212, 2021
PubMed
2) 日本呼吸器外科学会, 呼吸器外科専門医合同委員会 (編) : 呼吸器外科テキスト～外科専門医・呼吸器外科専門医をめざす人のために～, 改訂第2版. 南江堂, 2021
 
3) 日本肺癌学会 (編) : 肺癌診療ガイドライン 2020年版, 金原出版, 2021
 
4) Hamada C, Tsuboi M, Ohta M et al : Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer : an exploratory analysis from a meta-analysis of six randomized controlled trials. J Thorac Oncol 4 : 1511-1516, 2009
PubMed
5) Douillard JY, Tribodet H, Aubert D et al : Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer : subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol 5 : 220-228, 2010
PubMed
6) Wu YL, Tsuboi M, He J et al : Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med 383 : 1711-1723, 2020
PubMed
7) Felip E, Altorki N, Zhou C et al : Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010) : a randomised, multicentre, open-label, phase 3 trial. Lancet 398 : 1344-1357, 2021
PubMed
8) Antonia SJ, Villegas A, Daniel D et al : Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 379 : 2342-2350, 2018
PubMed
9) Forde PM, Spicer J, Lu S et al : Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med 386 : 1973-1985, 2022
PubMed
10) Okami J, Shintani Y, Okumura M et al : Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010. J Thorac Oncol 14 : 212-222, 2019
PubMed
11) Cahan WG : Radical lobectomy. J Thorac Cardiovasc Surg 39 : 555-572, 1960
PubMed
12) Ginsberg RJ, Rubinstein LV : Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 60 : 615-622 ; discussion 622-623, 1995
 
13) Suzuki K, Watanabe SI, Wakabayashi M et al : A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer. J Thorac Cardiovasc Surg 163 : 289-301.e2, 2022
 
14) Aokage K, Saji H, Suzuki K et al : A non-randomized confirmatory trial of segmentectomy for clinical T1N0 lung cancer with dominant ground glass opacity based on thinsection computed tomography (JCOG1211). Gen Thorac Cardiovasc Surg 65 : 267-272, 2017
 
15) Saji H, Okada M, Tsuboi M et al : Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L) : a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet 399 : 1607-1617, 2022
PubMed
16) Hishida T, Saji H, Watanabe SI et al : A randomized Phase III trial of lobe-specific vs. systematic nodal dissection for clinical Stage I-II non-small cell lung cancer (JCOG1413). Jpn J Clin Oncol 48 : 190-194, 2018
 
17) Endo S, Ikeda N, Kondo T et al : Model of lung cancer surgery risk derived from a Japanese nationwide web-based database of 78-594 patients during 2014-2015†. Eur J Cardiothorac Surg 52 : 1182-1189, 2017
 
P.326 掲載の参考文献
1) 日本肺癌学会 (編) : 肺癌診療ガイドライン 2021年版
 
2) Non-Small Cell Lung Cancer Collaborative Group : Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer. Cochrane Database Syst Rev (5) : CD007309, 2010
 
3) Schiller JH, Harrington D, Belani CP et al : Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 : 92-98, 2002
PubMed
4) Ohe Y, Ohashi Y, Kubota K et al : Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer : Four-Arm Cooperative Study in Japan. Ann Oncol 18 : 317-323, 2007
PubMed
5) Scagliotti GV, Parikh P, von Pawel J et al : Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 : 3543-3551, 2008
PubMed
6) Kato H, Ichinose Y, Ohta M et al : A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350 : 1713-1721, 2004
PubMed
7) Douillard JY, Tribodet H, Aubert D et al : Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer : subgroup analysis of the Lung Adjuvant Cisplatin Evaluation. J Thorac Oncol 5 : 220-228, 2010
PubMed
8) Yoneshima Y, Morita S, Ando M et al : Phase 3 trial comparing nanopar ticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC. J Thorac Oncol 16 : 1523-1532, 2021
 
9) Okamoto I, Nokihara H, Nomura S et al : Comparison of carboplatin plus pemetrexed followed by maintenance pemetrexed with docetaxel monotherapy in elderly patients with advanced nonsquamous non-small cell lung cancer : a phase 3 randomized clinical trial. JAMA Oncol 6 : e196828, 2020
PubMed
10) Kogure Y, Iwasawa S, Saka H et al : A randomized phase III study comparing carboplatin with nab-paclitaxel versus docetaxel for elderly patients with squamous-cell lung cancer : Capital study. Lancet Healthy Longev 2 : E791-E800, 2021
 
11) Noda K, Nishiwaki Y, Kawahara M et al : Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 : 85-91, 2002
PubMed
P.333 掲載の参考文献
1) Wang M, Herbst RS, Boshoff C : Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med 27 : 1345-1356, 2021
PubMed
2) Majeed U, Manochakian R, Zhao Y et al : Targeted therapy in advanced non-small cell lung cancer : current advances and future trends. J Hematol Oncol 14 : 108, 2021
PubMed
3) Melosky B, Wheatley-Price P, Juergens RA et al : The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer. Lung Cancer 160 : 136-151, 2021
PubMed
4) Reuss JE, Gosa L, Liu SV : Antibody Drug Conjugates in Lung Cancer : State of the Current Therapeutic Landscape and Future Developments. Clin Lung Cancer 22 : 483-499, 2021
PubMed
5) Nagasaka M, Zhu VW, Lim SM et al : Beyond osimertinib : The development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+NSCLC. J Thorac Oncol 16 : 740-763, 2021
PubMed
6) Ou SI, Nagasaka M, Brazel D et al : Will the clinical development of 4th-generation "double mutant active" ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC? Transl Oncol 14 : 101191, 2021
PubMed
7) Drilon A, Jenkins C, Iyer S et al : ROS1-dependent cancers - biology, diagnostics and therapeutics. Nat Rev Clin Oncol 18 : 35-55, 2021
PubMed
8) Roviello G, D'Angelo A, Sirico M et al : Advances in anti-BRAF therapies for lung cancer. Invest New Drugs 39 : 879-890, 2021
PubMed
9) Laetsch TW, Hong DS : Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer. Clin Cancer Res 27 : 4974-4982, 2021
PubMed
10) Fujino T, Suda K, Mitsudomi T : Lung Cancer with MET exon 14 Skipping Mutation : Genetic Feature, Current Treatments, and Future Challenges. Lung Cancer 12 : 35-50, 2021
PubMed
11) Thein KZ, Velcheti V, Mooers BHM et al : Precision therapy for RET-altered cancers with RET inhibitors. Trends Cancer 7 : 1074-1088, 2021
PubMed
12) Herdeis L, Gerlach D, McConnell DB et al : Stopping the beating heart of cancer : KRAS reviewed. Curr Opin Struct Biol 71 : 136-147, 2021
PubMed
13) Riudavets M, Sullivan I, Abdayem P et al : Targeting HER2 in non-small-cell lung cancer (NSCLC) : a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations. ESMO Open 6 : 100260, 2021
PubMed
14) Liu SV : NRG1 fusions : Biology to therapy. Lung Cancer 158 : 25-28, 2021
PubMed
15) Cohen P, Cross D, Janne PA : Kinase drug discovery 20 years after imatinib : progress and future directions. Nat Rev Drug Discov 20 : 551-569, 2021
PubMed
P.338 掲載の参考文献
1) Larkin J, Chiarion-Sileni V, Gonzalez R et al : Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 373 : 23-34, 2015
 
2) Borghaei H, Paz-Ares L, Horn L et al : Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 373 : 1627-1639, 2015
PubMed
3) Brahmer J, Reckamp KL, Baas P et al : Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 373 : 123-135, 2015
PubMed
4) Hammers HJ, Plimack ER, Infante JR et al : Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma : The CheckMate 016 Study. J Clin Oncol 35 : 3851-3858, 2017
PubMed
5) Dunn GP, Bruce AT, Ikeda H et al : Cancer immunoediting : from immunosurveillance to tumor escape. Nat Immunol 3 : 991-998, 2002
PubMed
6) Mittal D, Gubin MM, Schreiber RD et al : New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol 27 : 16-25, 2014
PubMed
7) Weber JS, O'Day S, Urba W et al : Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 26 : 5950-5956, 2008
PubMed
8) Borghaei H, Gettinger S, Vokes EE et al : Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057 : Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol 39 : 723-733, 2021
PubMed
9) Reck M, Rodriguez-Abreu D, Robinson AG et al : Updated Analysis of KEYNOTE-024 : Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J Clin Oncol 37 : 537-546, 2019
PubMed
10) Mok TSK, Wu YL, Kudaba I et al : Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042) : a randomised, open-label, controlled, phase 3 trial. Lancet 393 : 1819-1830, 2019
PubMed
11) Gadgeel S, Rodriguez-Abreu D, Speranza G et al : Updated Analysis From KEYNOTE-189 : Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol 38 : 1505-1517, 2020
 
12) Paz-Ares L, Vicente D, Tafreshi A et al : A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC : Protocol-Specified Final Analysis of KEYNOTE-407. J Thorac Oncol 15 : 1657-1669, 2020
PubMed
13) Pathak R, De Lima Lopes G, Yu H et al : Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer : A network metaanalysis of randomized trials. Cancer 127 : 709-719, 2021
PubMed
14) Socinski MA, Jotte RM, Cappuzzo F et al : Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 378 : 2288-2301, 2018
PubMed
15) Reck M, Mok TSK, Nishio M et al : Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150) : key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 7 : 387-401, 2019
 
16) Antonia SJ, Villegas A, Daniel D et al : Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med 377 : 1919-1929, 2017
PubMed
17) Faivre-Finn C, Vicente D, Kurata T et al : Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial. J Thorac Oncol 16 : 860-867, 2021
 
18) Chambers CA, Sullivan TJ, Allison JP : Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity 7 : 885-895, 1997
PubMed
19) Wolchok JD, Kluger H, Callahan MK et al : Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 : 122-133, 2013
PubMed
20) Hellmann MD, Paz-Ares L, Bernabe Caro R et al : Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med 381 : 2020-2031, 2019
PubMed
21) Shi LZ, Fu T, Guan B et al : Interdependent IL-7 and IFNgamma signalling in T-cell controls tumour eradication by combined alpha-CTLA-4+alpha-PD-1 therapy. Nat Commun 7 : 12335, 2016
 
22) Wei SC, Levine JH, Cogdill AP et al : Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. Cell 170 : 1120-1133e17, 2017
PubMed
23) Thommen DS, Koelzer VH, Herzig P et al : A transcriptionally and functionally distinct PD-1 (+) CD8 (+) T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med 24 : 994-1004, 2018
PubMed
24) Ferris ST, Durai V, Wu R et al : cDC1 prime and are licensed by CD4 (+) T cells to induce anti-tumour immunity. Nature 584 : 624-629, 2020
PubMed
25) Osorio JC, Arbour KC, Le DT et al : Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. J Clin Oncol 37 : 3546-3555, 2019
PubMed
26) Yost KE, Chang HY, Satpathy AT : Recruiting T cells in cancer immunotherapy. Science 372 : 130-131, 2021
PubMed
P.342 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Thoracic Tumours, 5th ed, IARC, Lyon, 2021
 
2) 日本肺癌学会 (編) : 肺癌取扱い規約, 第8版補訂版, 金原出版, 2021
 
P.347 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed) : WHO Classification of Tumours : Thoracic Tumours, 5th ed, IARC, Lyon, 2021
 
2) Brierley JD, Gospodarowicz MK, Wittekind C (eds) : TNM Classification of Malignant Tumours, 8th ed, Wiley-Blackwell, NJ, 2016
 
3) 日本肺癌学会 (編) : 臨床・病理 肺癌取扱い規約, 第8版補訂版, 金原出版, 2021
 
4) Moreira AL, Ocampo PSS, Xia Y et al : A Grading System for invasive Pulmonary Adenocarcinoma : A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol 15 : 1599-1610, 2020
 
5) Verhagen AF, Bulten J, Shirango H et al : The clinical value of lymphatic micrometastases in patients with non-small cell lung cancer. J Thorac Oncol 5 : 1201-1205, 2010
PubMed
6) Hellmann MD, Chaft JE, William WN Jr et al : Pathological response after neoadjuvant chemotherapy in resectable non-small- cell lung cancers : proposal for the use of major pathological response as a surrogate endopoint. Lancet Oncol 143 : 215-223, 2014
 
P.352 掲載の参考文献
1) 大星章一, 下里幸雄, 板倉克明 他 : 癌放射線療法の病理 (1) 癌組織の治癒過程の組織学的追跡 (その1). 医学のあゆみ 61 : 618-625, 1967
 
2) 大星章一, 下里幸雄, 板倉克明 他 : 癌放射線療法の病理 (1) 癌組織の治癒過程の組織学的追跡 (その2). 医学のあゆみ 61 : 665-671, 1967
 
3) Qu Y, Emoto K, Eguchi T et al : Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC : Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. J Thorac Oncol 14 : 482-493, 2019
PubMed
4) Travis WD, Dacic S, Wistuba I et al : IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. J Thorac Oncol 15 : 709-740, 2020
PubMed
5) Cottrell TR, Thompson ED, Forde PM et al : Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma : a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol 29 : 1853-1860, 2018
PubMed
6) Stein JE, Lipson EJ, Cottrell TR et al : Pan-Tumor Pathologic Scoring of Response to PD- (L) 1 Blockade. Clin Cancer Res 26 : 545-551, 2020
 

書評

最近チェックした商品履歴

Loading...